var title_f12_37_12880="Med bronchogen cyst CT V";
var content_f12_37_12880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchogenic cyst adjacent to aortic arch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan shows a cystic mass in close apposition to the distal aortic arch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12880=[""].join("\n");
var outline_f12_37_12880=null;
var title_f12_37_12881="Indoramin: International drug information";
var content_f12_37_12881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indoramin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Baratol (GB, IE, ZA);",
"     </li>",
"     <li>",
"      Doralese (GB, IE);",
"     </li>",
"     <li>",
"      Indorene (IT);",
"     </li>",
"     <li>",
"      Orfidora (ES);",
"     </li>",
"     <li>",
"      Vidora (FR);",
"     </li>",
"     <li>",
"      Wydora (DE);",
"     </li>",
"     <li>",
"      Wypresin (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Indoramin Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Blocking Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; benign prostatic hyperplasia",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypertension: 25 mg twice daily; increased if necessary by 25 mg every 2 weeks to maximum of 200 mg daily in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Benign prostatic hyperplasia: 20 mg twice daily; may increase dose by 20 mg every 2 weeks to a maximum of 100 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 20 mg, 25 mg, 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10396 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12881=[""].join("\n");
var outline_f12_37_12881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304137\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979070\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979072\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979075\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979071\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821240\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979074\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10396\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10396|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_37_12882="Division of sartorius muscle";
var content_f12_37_12882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Division of sartorius muscle for radical vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sartorius muscle is divided close to its origin at the anterior superior iliac spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12882=[""].join("\n");
var outline_f12_37_12882=null;
var title_f12_37_12883="Clinical features of hepatic encephalopathy";
var content_f12_37_12883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Clinical features of hepatic encephalopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 637px; background-image: url(data:image/gif;base64,R0lGODlhDwJ9AvcAAP///wDM////AP+ZAP+Z/wAAAMDAwICAgEBAQDw8PNnZ2dDQ0ODg4KCgoPDw8HBwcCAgIBAQEFBQUDAwMGBgYLCwsJCQkFm/2D8mP7KysgAzP39MfwBmfz8mAL9yAH9MAD8/AL+/AACZv39/ANjYWdilWezs7Nil2L9yv+Li4vb29r+mgMXFxQCy3wC/7+vrLAAMD9+FAA8PAO/vAA8JD++PAAB/n8XFhZ9fn898z4BmgOuf68/PAAAmLx8fAJ+fAAClz185XwBMXy8cL29vAE9PAF9fAC8cAG9Cb898AO+P78WrxQAZHx8TAI+PAC8vAK+vAE8vT59fAELC4izF6x8TH9/fABbI9QByjwBZbw8JAN+F369prwCMr49WAK9pAI9Wj29CAE8vAF85AL+mv+ufLAA/T/X1FuLiQuKi4vWc9YW4xeKiQllZWfDwIfHx8aKiojY2NvWcFkK10haixRYWFszMzNLSQtLS0gsLCywsLJiYmJubm8vLLDExMcuMLPr6+tPTZPCd8MXFFiysy/qa+sV/xfr6C8V/FsWrhaysrMbGxtTU1P//QNKYQtKY0suMyzY2FlZWVoWFhcLCwnp6eqJ8QiEhIaampv//EP//MKmpqUJCQj8/MLB3sIJpQv//UO7uICYmJmxSLK2trWxSbM/PEN/fUDYpNra2tuHh4aCgYK+vIExMTJaWlrm5uY2NjYuLi2RkZGBgELCesMfHxzfD5ltbW5OAk5+TgM/PUFBQQCxfbP//kP//IO/vcGFhIcCzoH9/UICAcLq6el9MX7+/kHBwYEJ1gsibyObm5jExIT8yP8nJyUZGFq+vgL+/gNzc3LGxsXx8fL+/MBoaGk2zzZ6entvb2+/vQGxsbEFBQYCAMGpEand3d8jIWdOn08/PMK+vcO/vgO/vkP//gIFaga+vMI+PUCAgECy42yySrJ+fMMvLy5GRkWdnZ7CwIY+PMMTExCYfJoCAYI+PQFxcXL29vV9fQJ+fgL+/IJSUlHh4eLW1tSoqKq+cryH5BAAAAAAALAAAAAAPAn0CAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzOBccOGDBAM0FEhA8ILhALkkECGo+QLCgYd25H/GiHYzWAYICiBEfAHDYbUsHEQogkEDQgGSPBwosFiiYZuOGlvNmzLwZAGLCqMlSKCDBAYAFDxZ/FujAgIG+BBkYYGDQNu+Buh0fXLB7oOUJvS8vwD2QOPOBtX8DCC6ddELdz+neNljbdWUD3gHU/wZvkPjAxt2h22Ye+nt49dKpD7Qu8LTu1Pi7HuZLMHPiA5YlFgFuqyEWmVsVRIYYYBIkVkB2C0CQGAK1OSgcAJZBMAFilL22IWIUMsZaYg0A4B9iE1Q4oWkFCLTAh6wV9OKErh3WYAEROHbigyYKWGKGH6Yo4o05YujggEaK1oCCBQBmI4k9JpZigCCyeCMEDjiAmGsVFIBcfmA6dWIEErhlgIQUAAibbQ1S1gCOFZxZwG4RRFBBBRIuYAFrBlRQZkESAtggBQysBsEB0hkZwQMPINbXhm0dZoGIDxiwZwQANNBWBZAysN8BJZ4GAJqWdjgQpAZIKiICB2zoJpx+9v/ppQFvYpphnJCu2mqMaxrQZpLT4dgApwWUeFill2a6aaefhlpAmpFN2uCkq5UY5rVLHSBhYhWIKJxaEmyY12HdersnqwccxhaOEiAqo5e04QhsQe15u0ABhx6w2rhzCrQhgukG2mNpp90LAUIGr7Wvt8A2aK1Ag64loW2XAdAlv2ZWDK64wO4JWJeUzfavxQFrNvBAolrXZYp1vofty0Yt0ADHs3UJAQULz9ZYZhDghVcDDhSI2IX1sjhvZRU3ZlkEPtul85yNTrCXyfQZXTS9ODY912ftzcaZl00TV3HX/bZnM86XtUcf2Y41FvXUi1WdssmjavYszHgTJcHDjVL/IGK5XF/WKGUO/Huxd/L5Sne8Ebh23NHGJT2nlhH85kC3n91bgJYtnpwZYEZT/lu5jFuOedmCN+kiA42Cvlu9DW6NOsbAml3x5wxrzrlA1uFeX+f0Nepo3sQDdRjTGyK5GtP6Zh1ZXgwwObSIyGuW2QQIHFhQo0wj1u3VAtX7mX94XXYY9pHNJWHPimUKImWico9AzwWRvx/D7UUP9uSR9Tzx0ghIHm8Cl5flZS9tFduQhnA0QLClr27sM9mbJAM/4NGNAYg5WPE2yBMGpAsvFvCOA/aCgAo4IF0PUIu1HGABAI0sU3FhFQNYhxcKZEcgDYgLBRzjwYcBB1Q4dBeG/yiAl0pR6mcCKRQC2gIggVgAL3ErTQ4nQzrjEFEubmmAu3qYRBI+wDUsxIsEQngcIhIqiLzh4gnlosLpAFE8T5TLb46FxOkQkYmOiWMUw9dEgUhoUhwM5FNuli583cRrPgGfRxCJEd0J8pFMOQyHbhgTRvJEkR2xpEVW4zdIevKToAylKEdJylKexQQmOIsKUlBKVJrSI66EmQIUcEoWlHKWr+wILmVJS7OYwJak3GUuNSJMbBVzLL+8ZS+HmZFjhsmZYUlmMJe5lQwYBZr5weZXpDlKbVbFmkXxJmpMYAdVspKUKTgnV8BJlHTm7ULMjCdN2ClPh1SALYnCCDzraf+R8bgsNTJbSxVRQk+PBKd4MCrAQC2yz5VoDmZCU11+qISilRSUIw7YFvHehKU9aRAjKcADTCTZuZhwkycBbF6xgOLOlaSqAZaa3lIkoKCQtFQqq5kL5/JJEXGWJICiMikweyKdDZWmJz4lydL+WRQLRGBPJfVIUo+irt81VCJTHUmAZnJSn0BGoUDJ6kf8A4GrDuVeMA2qVKkJlaqyyKwQEWtItiqTrvZkYWFla0oM0LzKqUSvGMmo3+j6EbkOpUGbGR5GDPsRwsLErjpxQIOElNdKLu4kF9WngxID14owNih7Qk6XMNVMwKrEsS95AyN+MqNOBuWzGGkA0DAULZX/ZPYiHlSYYnhaWqp8dQKROapFVLCIkX7ILteSnlp5EkuV7MhLTB3JbTWCWo6oQAVVoeHeONLZn2oNW03zWX486LMQWlQkueWnQrqr3vaKZLruFQlxz6La+E5lqPY1CWylAllP7pef/7UKX+EZ4Kf0F5IFjmeCTSLJclUtJA8GwIKZcuBHTjiXFx6JJBt3spFEOMNJqbAgQfwT/AqFxCAhaV7ooy0cUcA1f/FTA+pCAe5ZSmCZ2hYEAPNh027TxKBEcU/gyxMhL9JuBWgh1fBVyLxQFEAo0vGHeHOAdj0gMiWKcEjPAog3KNMrRN6JkTMJNXaZTEK/QfNxvNOe3QHg/4W1KWTcLhu+/GrlumB+5WdgtJigKq1i8xLVZyY4AYFFGEN2TvR79dwvzZ25AGmGdNHqJeh+RcY1vaMzos3SZUU7JcyCnI1/5nyo+026YpV2S2TSZGg6b9mXQP4knrvi457M2id7YU5crNXiCLz4NcgFtpNEk2uLSahdCChRA5JdkDEPRcSBdPYnpf0UagMF2hy0toVrjRpt+wTbG/R2tLlNGHEzN9b+JbdUQJ0TcyfF3TpZ5Ze7wm6cwPso5PS0Ve79knrf5KYvY6++B94QfxNcIgI/uMINYvCFOyThWAG3w3HS8IkrhN83kTjxmmtxjl8L4zbReN5A/jKSn1jdWv8ROd5M/nGUn4XldUU3gl1u4GvSvCwwF+q812nzld/c4kX+OVMqPpOc/wTiQOcJwLVC9Lqmsipr8QjSk67vpucy6h2ZelXkTXWgWP2VWN9IvmHddaDIPL9hJ6bQqaJymHnc4UuPStp7S/ZpUt3omBHuYtc+lbaXnO/qxXtH5r73Wu58K4CHieA5QviLLJ4lKvCy3endc6jr/SJjL3vleR7OxP+k8RfRuuZp8nasfP0lt54K6Bk6+q6fvpSrr4jo+3721svk9aSM/UReHRQPuvEjkG0A6A4i/I3wJyIP8KFEih+RJ94w+RtZAG+kvxTPw/7yFnn8QSxjJAzx5nW68Y7/eRggfQbUBjfmeQ35o9GPvpCf/Bj6UXHoBTTw8HD+28FQbabz/fQgyp+5QR7v9xsw1R1usRyv4X7g0R19YRvxJx7FYYD04n6X5YCsEj64ER0YUguKEB7SVxwHVTg2NAFnFH76txvSR0kzZxW6h1XWd1qasRoAIAGE8iCsQVMiGBcHwDyLskMPMAHhwhgQAAF14AfFsoOHoUV8ERt2Uj8IEBq+liDp8mbhMhdeEgETsCEYVGgHMydadGWjsyiVg4TWwipQSAEWcDAQYAF7cWUX84MS8AAthADR44ZneCpVaBmuBYRyKEM7NgEHgCc7aBkJkAAcxhhSMydrES4M0DMN/9AzBtCGjQM2SLhSoqR9o4F9nvWCexWDLZIgFoAc/WI3QDWF0UOCWuIWc2KGBcAC6DIua0Eh6RIBwpUu3JcuFwNl3aeIeTEnc8J9cwIbOiMbsUgQrGgidFgskLY/meEvECABasEqK/aELTKF3QeMwlFo0IguTNMz85M9mbEHCtAvjEGMFUABG1KO6rg/luEWU3iBl8iJO9GCEYGJWNN9AIBlpnEbvggw0GMbtLiG9+IpUMYIr1iO6aIthXMAejIf1IiMxPEmb6InXchXvdiO2DgZqSgQFNAaEKCExqiLU/grh/IabyIQcQJFyYYlNHiLooFBFLmPA5GSUPSI5mcAHf/pAORXAHuwCZDGGQeQUW9iAV3CGFujPoshff3yjppIE7UnZvKoE2MSXgiQJmtxlXFiG+thEPZIF3lRFwJxZa4hGSWEITpUfAygQw4AF2WZfGCZfMUHlw+QlhKwN2kyEMIHlsKXKhdYAZPRF3xRfHzBF2DJF6lCRBlIRIvBfGE5Y3lRfKniFkokAX7JkX9ZfOnyYnoJOn4JjYzBHEQEjdC3bEu0RtQYB3FAOgF0gU9ERBiSbC81mZ7SF3GpfBS3eaq3Wbq5m7zpIKipNVe5FjCllfO3V2sBVyRYH7MnEZT1MjxJTfBoFbjHEl1pEQewAQRAADmAAtzZnWCwAeAJnkj/gAHkWZ5V0JvomZ7e6DOxEZzEWZwQMUGIYZvGwWbRZWcGoAzY1Ry8FRXTKUrXmZ0COqAEWqAGSgBKgAJg0J0oEJ7hGQXlSZ40kJ4UulnhZZVr0RYAeSQmUV+2pxP/GUoBeqAkWqIEoAaGYKImup0M6qAbMJ4ROqEVSqHhFZwa6hsW4XcfahIhCkojqqJAmp0ncAJBWqRFmqAM+p3hGQTlKaMz2ptNg6E3Ck86uqMk8XREkXpS8aNGWqJD2qVgGqYEigMOggNIyp044KBM2qRPqpsTkAB+IBdXqZUq6HN3F5U5waViSqBfuqd+aqQNGgQoIKZnqqBLWp5D0KZSIkZz/+qANZFbmFOnf4WnplSdFaGnf0oAfZqpnNqpnIoCnoALDSqe5tmmjAoqjooSdagtMmke+yd9+7c6C+A46LeAr5NE5JGCv+GoGugAcNCjlUqpN4Gpf7qpnnqsyGqkhSAIKtqdafqi5JmoFIo97QIg5PER94KGvAE1QJgic0KCrXIePYMnP3gA5bpDTYI9CQKG86OFfEiUhxIBS2IPrbCcRwGsJ2GpFEGsfpoGj5CsABuwAiugSPqs0Zqe2JMmMNWfEeEnEFA5/biP0viMpXGBSNgzV1ZC3BcaxHiB3/qMddEzvhYBoiAJ90kV+KpfwmoT/OqngzqwMBuzA4umG8Ck0v/KmxgbiHDFQmwhfpXSJfdyJhYwkE41i8xxgTY5HpHoiwCQhjn5kR7bJ3yZkwwQJ3CQB005FSlbEnEHFS27py8rs2Lbqcs6tgTKneBJnr3JNO1SgOIBI0IymZHKlt1SFzIjGo2JQyAUR3Fyg7OqmAAAfXwRmrP6QVP0a5xHcF8rpmFrto4bpjuwBI9bomg7nje7WVi4WYA0V1H1MlsrSIsLpjsACZNbukYauaYbpFtgqBhwuUfCKm1xshQRq3jzuYEUul1qrKm7uwWKurzbpVuABOnJNHJ4rai3n0DXtU+Bu0aqu7/7u777vEd6s0OAAlywAVHgugYiF7G7EvoqFt//KxHMW6TOK72pG73mC6RKAAZBAAZKUKDbWbMYsJs9AyqSyhHYBH/6Fr4RMb5BWr7pO7lqkAYBDLBbcL3Zu5sk2L2DhwDHhJl4GxVYOhT8CxH+C6QAXMAavMFimgNpigFOmhgUWwEMa8EOTEtPBI0PGxskKAFVC0WB+wDQmC5xSAHGYq8EhZtbip3HOroc/MNAnKkJWrPayzwkvK8n/Ih+gmwmUlaHYn5dkiplkoZr1CoJIrvzpMNyx8PH2rhB/MVg3KUePJ66acS8xVd9xDsIkE7aIpxTyJQPcCirGDfTiEFV6XVGUXrLy8We6sVhPLDo+8diO8YgjLlm6BryaYkm/8I0dHgzD2DD8sqU6NgoqZKU6cov91sTtstBFwykfizIABvIoGy2W4ADZLxZD8uhuOqotgFjKah+3gce1IchvkIZ6BgUm7xBnWyiGTzKnSrKvvy4hMybQpQRNeQalBkUT+leu+ylRBrMAQvM0Fy6KBDCAtIuqTDBE1fBD9HMJNrL07yn0hzOj0umiXHKDiIXJmQSswwcmax/BUF+tKsQ+jsR86x4K1sT3nyg4EzOoiu5/sy7gRq2OcC+5+kgN9MAJRwRlrEYDRK4yseYCkGODgmWDCHR5RHBLvKVGv0S3OwQ+2yg/RzQJE3OJ5AMXIAErnszQxt6+IJBLQKXOOPCcf8pwy3kwn4ZtQ6JPWCZ07cRF5iTLsXnJwgAC3Vhi/viKVUZNJLR039Zjks0qSzIx5w60iV91b5srA06v0cyRu+cHBLwjC2CLk5cjJORGYIIxRGbY2sEjJUSIUO7jACSLhikRXlgGUTNfVlyJrpoGTCZhqaxFp1bEh/dECFtoJ+M1YoNzQBc0FEQwmTS0g83J3Yy1mZ92dzHKnGcGe2oxsjIfX65KKPY2bZoPW3gkqC9KIeysUyLjdyXEoXNEIddoIm92EA6wLYtvTuwAyrq2JBtwwv92pl92Uw53JO81nWIPdwHiFIDh6LojuPCKpfgkhiUfLRIi9W93FW4j6+NElr/usXJWtu5XaLjPN4c7NsITQEmtCTCQhuO8aoz1BflJ983Ccuvkx64Ks+SmX/pJ4C1ygf7B3/3sRzUF36OkX+2KqJUnakoat5dWt4O/sMFzdW8icMkkcvFM9sDatURTgAQ3uFA3KDa68JiZhTf7bULXqzPDOIm+uEsDrBpQMCdugH0q95YbEz5TBMaLqAcHuEu/uLI2uMmigKbVcgTYgEL/Uw5PhM7LqQrDuQGWrZQPrZCbqI4MKE0gAPZiQIqjdAPsFArUc8nN9VB/uRTfualW+UqugUGWspR0NWzFRER0t4V0QYd/ROxvRBNTgD+iuZ+nuZmLrMpfdAoguQPMRnT/wEegHvUlOnV0gjdL2bnFgPUDTDT5ndHTfvUMZHnCrHnBCDeQC7lfy6wat6pBX25O5bJhLYAT5tWeNIuvkjUjyhZFGDndb2D2sLXHRl/ELDEMsHpCeHpoP7iPz7qYqoGasC7SoADby7CX44hx5kbteEzxDjc7ViN0oiMdt7QVwmL8NjGbwR2Kf6nw87ixW7s08wFQeCk0vMw3yiv61o51s60dC2GFSDpUASIsCiFhOLIrmVKe97n6H7u6B7O6k7oBuIeuApGB3iTAd4XGsgHtRrfsGyCtHzjj7TnpW7bBF/w5KybqS52eazN4H2sG7/YHe/xKnryMWvNImzoXgHsCP+h8YGOrNe7AVwAs1xAnjnAqYIADgeKAUig8mHK8jBrzoiBA+rupBMQ51oh8wdB8wKrBInaugWAnQWAASQ6v2G6BQUwBBvA5gO7AVpO9Llb8+Y70ATL7A6i3hNB8pUFdeO+p0ZPojQ+9NrJBWRaBWG/BWuKBAl6nhswqH6PAUHQ8wOaA0wK+AQQBFlf9gLK7EKvBEownoefnWQPBob/voqPAVGg5etLnmBAAGSfnZofBTlPAGmanatf+eSJnWnKBVEQBYiPA6KfnZ3/+drJpLpP0nVfuut7szuW5AQBTrm10K6JEBg9ElBvEHve4AFrzhiwAT0vvDSAAds5/Y4fBFf//vhbQANgTwM0MKDfH/5DQACJWgV4j/kFEAUbUAUoMAQ0sAHyz+aIMQTnGQReD/ZBABBRCGAogAQJDQIFMBBAUjBKAS4DCxCQSKAKjQ1IqkisMqTAxoZIHoLZUmDIhiBRSp5MSdHlS5gxZc6kWdPmTQInTuDk2dMnzxwaCwyd0MABAKRJlSbNAMBAAQoPEABwYIABAAYLsgJoUMDqAgBawxqo2gCpAbBVqy5l29btUgUK3s6lW9fuXbxID2z4iRNFX58baAwtgCPhQoo4ghBcSJAimAJBNhD8+xgiwwI5UBTg+5LGRgJKNiMhwKUAmMOhFeb42M2cEtZBKG5JTWOI/2qBjivSoCGZtm6PBD5v2LD6IxIwsI8nB9zceV+dz6VPj8klCGGoBug2lUABqQMGER5EqHAgAoICDQ6kPzAVwYEHEw5QaA9ggoQJD54iiOA9r90UUvhvQAILrGsv6mCqLEGYlKAoKIVSwwyJzRqbiIDiJCOONoqK+8vDzTpzKUKKQiTARBIj5AKDwYYwccSFUrSQIsdyiKKKAmjYQjfHPiJuA8NWbLE0Fk1i8Egkk1TyJiXA8GgoCA64qq2mEHggqfraq++9pwDYEr7zykOgy6e6rM9ANNNUc029RExQDUOWxBADHFC4jq+PUNgRIhwiJIiLHFgbggsUkMjBJdaiQP/hohM5g2kkFBT9LNLMJFTITi48yQMh3rjg4rYIH+KiONQeiuKgiehEgaAceJzooQ1QwCHWIAjlDVMUeJNzV157fS6HIAYbSoIK0CsAgaOaaiCCBip4oAEIHOjuSzMhMCBKAwx4oID2GChgAQusLcDLqdg091x020LwyOiWXHWoKjorLrMcBmOstMFQ+3SoIThMDMchDn3RJSWC/WiLHDyqwjBLMdjiyXkOtXGoGBdS4iEaSCMgBxyjCO6hjwxzNTSDMXqY3xxONulQX1t2+eWZcCAIu6GmYgGpBhBAoAJyKXCggSufXWAqBrqjoAELdK4AaACKlWCBobm6Ml2qq1b/c10G24V56752WIJrsMOmSA01xHZ5i4ZontJqtpEKsG248cI6Qa3Nthsmr+/Wm9e6916S5gLEWztudOMi/PC35qaub78bd/zx5hiHnLqZAd8ZcXMNx3zzNpGUfHLQQwf9c9EBU2JmDJTgIg7Cohyc8/80hx1xxadL45HSc9e9cdJ3/8nfDLbYAMdheaZ6rczlmp12NxNc0Hde1UgDeupz2ql66jJwacXWLTiKLgeMnXquqN1CAKy8ZF8+7tqnex77JPOGX/c0pp//Oe1fQlvY7M464ADtYClaDuBZ0p42tAMQSwIWKB9SFiABBFigKxMYGtTOhwAKXK49PmsABSTh/4r1Ha590nnf/RIkPxOmUIUxyV9MZEaY/GDHLA6MQAEg0ABoVUACEnhKBSAggfV0ST05G5N2vAIAr5SpAA6wALOiNS1rvS6EVhuhc3YAiRUyCIVZ5OL9WigTYPGPMBFIylW0xa0oHaABXeKSV8Y1xAdCYAJINGK23OgUbk1FS+WaIvuaN53edZEnWxRkIX13vZo0CXBTMg8CIEABBjzyARRgIwDvmJSo4AcAP4ykHN14gPyEZzxi6iPhqhg5RBqya19Tpd52sINWUkeMNjzAURZglaRkywFr0YpaAvidbAFzl2SxI9SAeZWsqK+UVDslYAIZS5lID5p2e+Y0a9Inwv/wjwLoo1oD26LMZaKrmdBJpTXNObpynrMnKEDJX15YsxliDpzhNNc4f1JNdeaTa/gUJCubA6wxSglx86TnmuzpkyvqU6F+42cXv9gcJQyPMJQkHEELmqaD+qSEC6UIITkqp4Zy8aHPeWcBioKXbZkUAM+6i0UvaqCMrvOjMfHoTOMHS32OVDoAHUoEakmXp4ClAQuIwA1Zer5JYtABD7zce/j4Uoz+0X02fUlNqXpV/CkposSDCjfZ4oAJBO5K7wEAWb1iJQdAIFwMLIC3AAhVg0r1OSGFplWxetef6JRBJUVAzmr2vV0uoCsGIKtZCXuAsgaRjkeE69Xk6hy6xtL/rnil7E1wuiue0qxc+5nABBxAgQkYgALnOauVIsCA+EhAFCpgbGPRFFOcRLaVk61sX+pX2wRFdJFIYQBacmlGtViJLA40QFyG69rXPhaVuGXuXNPZXMAAjod3YSlclIfc5HruudDlLk1k210aAc6k8YzddbFbINje5Lvgxet6vfiy01EsjFD6afrMe94BpfcmG+WoNNlLToXqlVf+2mpPIYkXl+KXLvq1CX8XStv/ysS98xMwzHDwpAJMty5vUzCBGFwTBysUwhHG22XVWeGtUQqeHa7ah2cCp7uOmMQ2RTHXtmAwGxqFxedysYS3+2B/zhi3NQZbRIXl0+/tOKra/41xkIX85LDhgHj9uQoTDxALVSg5Lz2OyYS7WAhBQFm9PxbzdEoKWhgmmQH/k6KWvaRcZ5K5zJT18pxn8i7AWeAsUJEKVXCpFrAswJa+dS2XYVJnO08T0dQzcelaRTP/dOc7oiTPfo4FAQgAgD75KTQGfvRpUIda1J8uRSlGfWpUp1rVq2Y1cTDwaljHWtazpnWtbX1rXOda17vmda99TWtUoOLXwyZ25cR7bGQnW9nLZnaznS1ePZd1fFka07jaCAALSAACT33pAZihA3CHW9zjJne5wV0Mc6eb3P9jd7vd/W54x1ve8/7fP8hwb3znW9/7vjct9pEtgAdc4AMneP/BDX5whCdc4QtnOMPhAIeGR1ziBE9y1ZqCX7CmGWfMcha0pEVJa1syqH1u7P/S9Us3n8sEKE/5SxPc8rdcHOMWoACWlUJEnm1wqVMR2lQyGJVCIxZdLIe5mmRe9IKqQAVI/8/RmV50k58rBXh4+pqcXnWsn/fqWVdy1JPHdQNtHexjp+fNyK5lr7Pp5WdfitnZDjulv73oHAZ72te0drnnfXZ41ztc+Y52oX+974Mv5d8JT0/D79juakr84R1/rsbD/L74jbyCF58mFSzi8Wxx++arVvmUix25oD/v5dNE9MeL3vN3nzzbVd9Y0mPX9GhCveNfv3o0xV7Jt4dq3Mf/PnsD1f7wvMd98etCfOPTLvBqb73tk/98AiEf+nADPoF037atLAV5bDkuXsSiFKdnn3Din76Sm19+zFV/QNdX0wIgEDjykispUetSW873n+omjttqYtpSmNZ/rjMBE0C/gmI/uFK/8uojBJAArDAApnkWUKKAp6GAYymTqeigpDifDqIACigWtMCgnWEAnfGZnoOPBcggxGqPCeAjpkILCOKZB3iABUogBmiAHXqaB4QW8SgWsoIA8WAandtACcgKCIq2HTNAAmQ+skNA++qjrjCpBfgSUAKAHSKTJSIP+UgKrzgACKgAboGgp2CiCBimKGmjCnC/B/DCB4iWM9kk/+9xP7YSQSAqAB/6nznaISkkGgLaQj3qqyeiD2spwyLSMiRMQsY7P6RjQgRDRMRhgKrQmTwkFyvUNPRYGz6ko/awwgoQjzK0JKQoAE74nwySv08MoCM6K098D2qLxDUMolXswy+JozkyP0bkOulDvFpsOUXEC+HDHEfiDxw6Fp/iQvOoAG/Rj3F5CgbUQgOoDz58ClB6Fp/yqWvzkjpIoGWJDz6KjwewgNSao2tTxSghj67gDzViFtDaFgdklm4RD/L4kkyaxSPMRay7xXAqxIsiRngjOK+ai160mij0HqXQJQfKCgbIClxqwLXwFuM5C/AAC7JAyG9BH6jRil76Jf8+8K3eIr9bIq6C5KU1G5MpscirMCarGC6o2YqqQKZAc8RgIkR6rDp7XCZ8LKj1eDbxWkGd2UlVdLcKGLiKS5MnDJx+HBAdugtv2g42AcDio7u8m0lDZJMDEIMPqEqr/IAw6ACt3MoOaAKc/Mpj4UkgarefBDg106yLgsqoHL615JwD+IABiEu5nEu6rMu49AC8zEtL+ISrtEqu3EqwdLb/sYCAmyK1bMu+O0zE9DC4tEvHfMy5LIESgEzIjIG8xEsp6Mu/DEyi2MkHYLey/MfcW8wkHMAd8726a0zKXM3InEzWfE3WrIEOwI4wqMox2MojCMydHEs1AjjSZBun/E3/eYpJtFNN2KRMyTxO5XzMGvgArfwCyqyBy7TKrNTK3MTJnfyfNSpK4VzE7uScmqSnt1xO5HRN8jxP9FxN6cRMqxQD62S2FfzMNWqzcOq+cyG/0wtKpQhP1zJNFuPPZRrP9KzLMviDAT1QBD3O9cxM5+zKZNs2+vhJ/cSclJqj1nILpryLNlyK+8s/8wGL+3MLAIUrxVyfEe0jAU3Qu1RRFm3R11zPqhQDPdACZFvA3pzQqgkqrkAiqdAzp7Eg+PDBB3AAqSBBGfSOEyQrFeQjCMLB8SqqoUJBBBqTCaogpoLBIzUcpmIgEKwAHkSsGJS0livR5TnRKUpRFfUAF11T/zalzAyIyyTwgKrsgOsULxv9SavJOPFAov9pq28Jlx6KQp8bE7VaQC+8ljQsgDV0gDYkwqk4oh5MVAugQwiiIzpSqwVoK0MtgD2QC50BuCVqIkc81E0VTeQi09kJTqxD0wRV0zZ9VVgdgDd1TOnMTPc8tm3rRvtEk8AarCS6IyXSC/dQxcNaLPqYjz7krf7QGUs1q2PtCvk7xTKhI7NShAGURStsRVS01ND7zrbJhTFo0eSMVXJ10Vl9Tcv0Auf0SsA5D13F0brgLM/6VfvAD2TcuGaBgElKGsTawiiRgGxcQd5SVIHlJNBqxn9dD/njJK/4xsTi1niExvxIx2290P/d81a2WYEOEFfzLFePPdBEGNAk+IIPEIM6xQ53Jcy3sDKBbED0IQvk8a3tM6aq0A6xGK7eAouN5Kad9bOjwKWcXci0IKZBK0inAKxgCqqX7a2lAq4xxVir0ViO/ViqrVrKtMwPuE3x2rYDOMPvCCuigFekS0qoNRcBJDupZdFxtVq2bdu6jAGSNdmcBFvCMMKiM9Oyxdv1SVsVXVu3/VvAhdPM7AAa3VpjRDq9xdjEnR2+TVC/DVzIHYCQbVvpFINjOw814k7KI06m49x79FwWa1wElQNEiFzTlVXArYE6PYKstFOh6bDFXSZUhZ3Y5RzRRVBXPd3APVe3rQEvEAP/L6gBuYRb5yxc7LCSwz0eU50LJpohw1mzp6RFtN3YFs1d3f1b3r3e4SVZwqUZzK0Asf2P+jOQcEEfRRgX6JW72eWcsx272x1Q0tVewM1e+aVL4u1e7HgkBjq9cUGKNbwh90MACto2eXS/FUwrZkEKCqw2L8E0fS0ABlpBCKDPiy3bdHnf9Hzc+qVa+t1gu0wCKQiDk62Zrg3ftqi/TCWgCGiirmXhhpSAK5kAC2jDSQQlB6BDqYAgYmS69bVgpMBg9NRgDy7XMhji4/SA32VXGHoWCl4KFF6iTfwZdQSab0EKGLaPGeajGn7UZlxAHiK0ous8H14TID5PITZiNNbd/xgI4RF+pAYoyffLsCR7iqHQFkzDITmKoDz+HgNGljZMq9AaF2fs4qGZgBsaY+sD3Q4rY/I84zR+5NOVTuekGR/EDv+gmtoVzkzGHEZeTkeG5BYtYlBOTzmdzXZt4txTZERuKVXGr05WTjZwhFGO1Q6e5eWUgq09GlROwL4T482dXhe1Xls212Ee0Bow3gJQYihJQxOui00OoR4eTmCu3mJm01qu5tdMAnYVA+EtZZrJj+X9plZ2i+/TvnDOpfAt56aTXvelXhYVZmxG0GuO59gU3rr0ABHWrP1twrZYgLDyqf8gK7Yg27oI0bcQ6AGJZsRBTa575eOMZXpm0XmO6P/0rIEvCANl7o835lWAZgAuNcEXJJch5MHD8saViraoCdMZHkIb3KEF+NKyEiwObJYX/CxHWr68UOiydWjY/GSKPs6O/WkXXWMxQOb8aMi86BKpQMYzxNT0SA+rUNQPtCRvCSA2msM6nMIdGlU3Qlg7Uo/+YECEXudVJmN3dtygFmq11t4kmGTsWKBdLiOvSNL6k9b2oMNiEY8edKRcCrlKojZtLZP6gMb/KSycxgv/7DCGzjqefk2fXmvIDlyLxuj87cDvibuATLL1MGQGXqn7CC0gwsJoVFII7uvE+utxrACKFexygcQJ2ETzOOyxe+bDaWzWfOzIzm3AjYHfReb/CCIFBRjKCOCmqhja+QugW0Im3xKLrkgykATJTJySk1QL8UvusEjJvKNtwrHt1cRt3abLif7uYM7n1kFLqZTttsjQ8tPuuOFuyoxf8YbN8I7voZaCohYv12NnsHNvyoRn+nbM+f5vFy2BTwAccB47na6occYu/oZM/xZw8IZwqpVMU27Xo2lmFkvwuGFvuGnwx3xwCY/LAA9xBGUDNmjO57ToMVDmCIpr/NJwb/Vwu/Ru+h5xEn/Vtj7Z/NDczVGLE25mGP9OGa9LGr9xI7daoq5spB6QsSYQTmoLi3WLIO/OIafLIj9yLKdaFTfe/ljyuxBom0YskibppPjRCcpA/xTERKVpmgXMijRXsvbd77NG0CvPcjsnzzIQZeW8aCWOAIDF8IfVNAlIq67Qj0w19IEFl0xrLTrM1Ey1ijXzU62IpETlcdfi8Lap8ta88wFIa04/0DqfyySgbML484IWOsPO6zTkj6mZREavI69YQQocX6hgM/1u6DkHdU+/cRv/9NvedeXM8bfWMUZdc6T4xTR0RwaQj/xg9vH57CthdAm00GvZoXG5D0oiRgmQhltn7Fw/UBAP8V739fJkUd4+WfyQIeLSSJxl934ktO6DaodcSatGn5ydcqvB9Iz99gENdwkfd3J/zFBfzXPf2qoxaLzA989bcOTS9Ln0dwgH+P+An3FgR9AYCAPA8fLZUXiqUdWqc/i4LFBOl/iJp8s8h9UYEK8uh+ayNuupvfOKL3nTxeWh0AJSD5wO3PiWVxOQ7/SYl3mgZ9u2Dl44vXl9tfSq8eWd/4+eH/hylc4YGAAPSAI2tUx7lsv1RNA4DfqPTYIxMN6jRxP1QG8HYkH3EKwr2dX5c/EC2T668Pina/qfT88k4Eqqf9sPeHAPKAC4LAB+r8vMPM4PKADrjYHCPc8YyPu4nM1PN/HA/YKv7x62vzmoOFqU9K0w1A7oTaI3huCO7K2vPbCOVIrRZ1qsmHSn8DPQ3wqtGKyz4HF9j9q/N+O5R8/EH4oPiPq4tMz/u+R7rJ/63u97d47Tqx8A4h8AxmdOvNT9wbfewYfOyrRe6aT6vTdOudx6+4V4oXb6NYV845XhybdUk8I0TYtGiWXgZ4QKL2QACeStbdOWz04KbrSATRyPNYuAsJKA/ngKbQSIAwgAIDhwoMABBhAeTDgA4CHEhwoURKxo8SLGjBo3cuwIYEWHASJHkixp8uSAMn9QsmzJskABkR8KHIF5ZABMmAOkaLFZw0OBDzhD1uiQU8qAJE1yisn5YaaHAVBx5gwjtUBUkUBhPsV61cPMmjRFhmGaM6bRATXEaklyVexNl3Ln0q1rl2WJEnf38q0hpWlOBA0ceCxgAIBhAwUA/1iQAAGBYgCKIxsWiPjwBAsRKkAsePkzaM8FLVeGvFix5YKRD0RA8BjjRI+yZ9OubREkX5dZc9PVeTWMh5oevBQY46FGATEDiEsBKrRAyLJJajRpMsCoWy9fhMeYOlVKjS9Lv46sMaaAl+5eoc4ELhyo8u7EjV+PWfa4lpvtg3vl7f//f3kBOCBKfgEGkwSDQbTAARYQ9tACBVhw2WQFLPCAaYzVQZkBpHFmQQEQRITAAwBAYEGEDDx0ogMLUCCBAxA0QFqHGVoAwQEQGICjYg40AAEDDhx2UWy2GXkkkhDhRuBIuzFpkm/eYeXcAFs5RSV09Z01FElpkQdVUTT1RP/eSFJGxd56WE2lVVAipeVlWmY+OSedIwlY55MxeCFWARFQUEEDOUWwwEMYDoTAAgsMRAECFDygqAQSoHjoAg2UaAGiDiAUkQGCLSABApxBCKoBDjDqkKUEVfqAYpEuwIAEFFDQAACMAtAAAghMSCRFSfr6a0dLPukknlGm6QGVMSQ3UgxYhnSeWwPEMEB1NSQVg5czeTHAeWAV8EV9ZMqU5rbdmikFeiJ9QWW4501b3Zf94TlvgHrRm6cXS50VmG0ZbFRBASoCC1FkSZpgwsAJK/yQsASy4Qi9SRgFXRJmKpsftwU00YEWHzibVE8d1LSTxkZ5cN4RXljZkwdfaCz/lrjkrazmsWtBt/HFN6WVhBZN1ISUnPcKvZcccgw9ZxJh6HtWvxsxQOjCQi48NdW2NTzgnXh299QHzXZd5ddgbZvUU+B1dyZSaknxVLR6foBUDV584BZY6379xdtrgz1tk1+DbbfX04LFN95hf7Ct3tLKHe3gex/9OOSRi5TEvgVkJrBH/la9OeedWx3Sk1lLPjrppZt+OuQTVz6Bghz16jnsscvOMOhMio467rnrvjvv5X3QQQdfGHhWgg/ODnuRxx9/NYC39156Is9LX+/0ucXNp5+iKr958tvHzjz11Zeegfjl1+W8+XPpuXQEj3o/dffvdw6+f3Igkr7k5OO//79J6PPvUtKWhiOBsUB+SYqfAatGP/8Q63/z0p8D+ee/CLbkC2PoCUwyg4kEHgmBHFzYAnnTQArOCYIkNN8ET8iSvxCvdR/0iAdfOLAQ8sV+KsSTCW84vRTq8CR+wd6fZCjE99FwLzzs4V7KgMQlLpEP+RKU+4YoRdgV8S5HZCIWs6jFkugvgDkZ4BTDSLUq2uWKWzwjGm+oRJJYEIOWc6EMVaACMc6wdgQyYxpLssY8mq5ofLQLC3MSxCRJDUkOsACtAODBBhymQ5ijo0bIeD57/ZEuOawk5PCIyet98QGPpE3BjnQjqHnQMxE4gPEgmRFJ0uVhmLTkK0enSSbusf8lSXOjYFLpkVA+AAIyWsBjJgBMBExgQRCYAAJiFIFEuqMajXKABCYAgQoUJFDFVOVGWEmXEcaSi92M3CyXeMkKHshPUNvlYgAQIQdUIAKaOUAF3qk9CZQoM5Z5SDQPsIAbCSRXDjEMNrNpRwJx85siGadB8RROJCK0JXFbGut0iZGCrbOdPnqAYSxlIXzW0wL3BMA9vCEBd+rIAJ3655ACihFtzqWgBm1oQue00B7CVDcXFGRKJ5oTA/RSRj9C5o2Q+SBgCvWjFPDHQkx1zFOBRqUXYalLVBLTk1ByqvNiAxu+WVO5/PCLDoImTCBwTqd+EKotmalV06rWumyVLkn/uGmfIHCWCJBVhmbFS1XXqte9+qetdelq5XJaV/ndFSVo5StiE/sknu1Lewk72GBpU1iq5tWqflWsXMpQS8zS5Tz7EozCYhjZlQ60eZWd6mU5i1fV2qUGgGmCZ0OUEGCJdrS3Ke1/pKrX1LK2f6fl42+ZxLfuLI0CgrVNbW0bkcmexKVa7S1vDqtC3gJICqqTkURlk1zl0o5Ozu0mdaErEumeMLwAigFc2/dJGL6Ou6vE7X++G0vzQpe8JKQvgB6KU9pA1r2RhG90gyte8Wr2uaf7gupY5986ylTAA37wfHOHXgziKLsLng1zS2JfCHP4htHTXQ0+oC/1XthIGSbJ/4aZ6OAOs5heUuATBdb7kBSkoMRPBXBuUizOFssFqzyekwdUBxmLbJdgFq7IqwrJwRPbacUR/vFqoZyn2BYkAn1qQJEQELCPVgRRSB5Ilw8Qyot4+Xs4zo18X4lf1ur4fx8WH3orV4A99ErLFLCMQChgPEQ1QFYSYAAFCpBMDOlZNYupAKg4k2drjpVzTG7SXtes2jbzT9KPw9a+OFHnB7RGMBCAJgUgUhkd8WgxjNoRpsQcsALMaJmfPgxAzezdSEvZsE7mXbOQpetd87rXvP5CG7gm7GETu9hhAB6yk63sZTNbzs6GSRvqbBBB4xnMl0mNqgkympNWyCAGsXasqf945iSuRK+braSv061uXcut2MIexSjcLWwxMLve9gbe0p6t77nmqt/+/jfAA94GbxO84AY/uJhNqvCFM7zhDT+yZPaVijkSBJWtYUD7NiPqGlWcAQV4QAUWQoFUR8afE8A4hkz0Z1mH7tZIzPW6Y67rwsm75sM+9r1zrux98/wsyAw40IPeKIQTneiMdDjSk26ARidQc9hsgJWXGZFXqZNQQnpkqZ6mThUx4DBCOkySh7QAA6jo6gAQEsQVVkWZ79oSllB3u20u9w/QW+d2z3fPn91pofPd30X/u8GVLviH27jwAHB6QGVseAAEI+8/7zsC4hCHoN8Z8JY/+uAHz/T/zSFs8Z5XZXs/P9hOhTb0ou8I4k+v+tVXrcjKJX3CXM/61LM+drKvvRhvH1nYD8wEdsA9R2gPfM7pfvhCLH5deT+w4xofIsJvPvxMr/rng176JVY+sJgPfepDP/bWFz336Yh8smL/V9pvfgG7T/zvfz78uWe/f8ufpBTgQf32l934uev++3tP/kjKP/8FoABWxP4NoOz4XwfBnwEuIAM6XwMmEAIaCQAaXvo9oAVemByJXgQilwLiXgFeIEZkIAh+0ARi0wbWRgna2AeOYEWkIAv+igvS0QnShgosggCu4AtKRAcWXufVVQyK0QyC0g3mIG38oFPhoAwZ4RQF4Wyc/5/xIeELKmFAQSEJ7qBtMaFH1CARbqEODh8VchCNaaC10ZYVchDV0QbaDYzWQYiMKZlGlArwSSE2fSEXgtIYwmAZZoRiwIQTIkmqPEAizQYErBywfJRnWMSYZUSZ1eERMmLnYGFHpGDBQFOpIAqoSMACmAoCFA+jJIiLiIZAUJNnQED7ACIA5JmP+BnmUBMmWlNnCMSEsCKhFIRg3IKsUBPZ5YqeGWKk6BmihQpqQAYD6KKp0ApkIMqnhAoAPMADYKIjTlEFPuPUDEOI6KJBHF3awUYe6hRMqNMx0crTgMqLVNw4FsRCAEyEiFmQAAzHVdOnxUqO7IhDAIDH7ZOIhP8bQhxEPd4IYojZAdQBwBwAqDiAkOCIIT5AjGBUqynGLxKkPDIEwGgKqqXIJsKhNEpjf3kePfBcpz1Ag5jUkUliOj3EBBSAA2Aco/hTxYFiAVSexx1GLx1EO37bKdJixT1EZHDIxlVIxH3GAejBtYVK+xiktYmGlnnbaghlTHpco1wGQBnGIXpeRl5k58ihECmGEYRACDjBCIxAEYAACPDcY0jARx4G/ZmfoCGKrDSAMH0cUJ3SKb3TKeWIQE5GrUwARhkA1OFKQmRcBWAbRExANJUIPprUYggmXvokUJYG1LEGTT5ErnDaMBbEBCRlY54SQTwlTyHmTX6eVVJlC27/Y/IVwAgIgGmeJmpagVZ2pRGAwBPsGzIZxNIZydeRHRySXdc9zdexiEmdCD3OpkXaJmEkCtWZndadIU5CjUVKhkMmJ04SBgNMSNYRCnEywBpWnUWOXZAcxnEmCtcNCRyOHRuK3meKX2SV5wcpRmmiJnu2J2pqJVe2pg/o3dBVgBP+pWNphKJ4xn7OoxDR4QWiZxgBqPwIKASSpnsmqIKmphP8wAjIp7M9xgNYgEWWZAZdmGiyoIFKEYG+z4bKj3ouqIi65wv0QXvyQAiMABGAwHxWTgRYaE7sCmga3of+Z2RNpeGF6IjuqGmSAAnsKA9AgVe+ppw1BNnNqI2FIfB1/yiSEgyC8uiO+iiUoiYPGAF9HkADbF6TbunCMOmW6uiULqiUhqlpWoEM5IQMqGhYVg6JZOnx1CbEzVZEpB4jHUmd/sqdcqnnZKiecsqTkmmCjimgVikIGAEPUKmQgsCZftbI9WH2paWWPkS4PQSdOqoi+meS5GmfDqCSeh6YAmp7CiqojqgVCGkRtKjPzUqkJslkHIZnQOUESBNTFoAELCME1AGtCBq1LQAyidVDOAAxiZVi5AqEPAaO8KprMOVr6CqyihUxCVMvsU5BAKs0MYgvRYClylCnbioZauCfjipqlii4kukMpOipsikgrioopeVNQqVDNEQBVAA6mmQl0P9VvN5kh+DIQ1hAMTVjj0AEPVUcqNClYUjkvQ7sIH7cYESApAxjg/QrWRZTQzhVjT5jxW7Pp46raYaAxo5quXolqgYGyCkeOnUGQrorAGRGYlgIvdqrqzbINE0sY0DsmAVsQUSKSUVIqbDsYeCswrEGihyAYBYEvy4jWR4Kplbf8EUjxfKpSmWsxnJsx2rsxyrqvrQGPGVjReyhYYCIlnVKrCbTytoqrn6GajAsZp5dsI7dSKoT2upTsAaKaxAm2AVrL7nGMMnItK4tYKrUxX6QlyrP3x4P1I6r1E4t4pbqCFjtWQyimF0EfnZEVCrPpMah09pW4B7P4M5O4Y6qqCL/LugKAA/8wIqujqqmbE5ck0Zo6vHIqfFtrgFl7uyIoKd+q8Z+bujmrgBspRGErJzJKLfWBo6unuyCpmI4Aejiru4ub9Uuqs9RaAcFrwdKr20oxuF2rPIur/aa5gg8G4lUAMleRPFSrxj1IFnR7uJZb/L+6Pa2b2o6b5qea+NKiqOOL/mCJuzGjvoibva6r+4SahEcqmnOQKKiK/iKr57mbw4qsOfsL+Jer/9GsILygBPMQjrsyyCiiAP+CoPoE22kiucxsIZergkWAARHrQSn8I6GAitwQyew6QFMgtZuBNQxI12NHaE8jXWWCtlRJwPc02xKjdblJnNmp9jBIRG//5AIK4/97ikJq5IDT+0JqzAVu6cmUEM97IJc+Rwghq9GLFPXccad4SVrCIbl2ORoDARisspihOIpDYTl+FLKvgiJNMSfvHESPvFgNXFV6rEMmjDonsEgVDEh76gmnMIqMAQGz4oXV0S8suViNMZj3BNAYZtA5KRhtHGoUBuFZDIxfVxryCsnK7EfkxUfr5+3TrHnsm8ht7KINsIviINALHIDNDIFsA6IKMaF2KRPktq37aOOxCuojF2gtOqqHYZ98pSF6GXlFmgpN+L9ykYU3y4ru7I1t6cbHIJpNkI5QMMsc3EFGA+DOMjZYYpnMIqjgLCXwcpapoos1go9sYpKIv/jQBiAOJqzfarkC6Hv7EWzNAMy/1bzNQ+0ANzAC7RnI/SCMXxzYDSIoKirP3PQKTPiNI9r/xI0IRu0gmYCKIzDMyiynN1hRF/k8NpYRYPrRWM0FWv0iHI0OeSDBFTOn8ww7vHzSLNXKoMuGtyBShM0S0OpKXivB/PfEoNgUVfNSYOrKvf0Sh90mK4pTKDDMcBon8wKTXNEZGJEYgTiK27cJZ8GV7feM/vteY61FCX1qC41U6dwILgBuS4uCECBaR7yKlCAlaXu4yYJiBCKP+olIyWEa2SpbBLEhNJKQgjEDxOEjEDvUJeeF5Z1ToOuWq81ZY9oI+iCMFA1w9aykRT/DK0axClNxi2PnQGg4ya2UzF/9V26CCYGTPQ99mAdNdWgNaDudGXf9qhmQjawAz5scQZF0T9L6mFQMsex5deyZI0kpTq1ZK2+9pJG1rbmKEBPbUrjtnUvqC+EQzy8sKBYdUcEWq4ON5h1rVhFCjs2SjtNhmqPkoncq3NP702/4XRjr0Bft/+2dQqz8CzcdQY19kVc4ymqiF4+REIcUi1jaUI0gEcNd9cdeDnTSi/N6ETXIW2TaXXbd+j+tAqbwggQKUxkD0H2U35Wjb6CJtPG99bONzVjeApreBXPwA8YgfOGyFmENYp/XnQXXoWH6YWz+NS6eCvzABF4+BfZVknf/7g2RvbUCrKPRzCQWzMUyFmCNDJteBuVH8kCxEGvmOLUWZuiqEpnvAqhgHACm/UQ7XiYTnaT/7hTY7QV6BteQnRhyEqszaY6ceerqIh4ft2DmNRDdF2fB0qvMBLaNZJJcidKwWFCjPaAS4bV8fCfHykHnXhAyfbUoPmUqvmab/qI/gCa8oAVOAFUVzUc1QZAvYhCMMQBMMSEljFb0vGMSKZgTiiGcJoDCGagSduw+smuG9diMHcESGRgW8Ya93o7cZn8TDjVWPrCYDqUajqnR3uC8sAIOMEMoCYBy/hZ6IqcWwRAYUgZP0asWcawluQuG4Y0tTYyIcRpFICua3JS6v9kJnOcavNkKI5y00H25zl7lNa3tP/7uFI7kZ/jbEjIXv7IdrIIgwzESwIAK0pkPruGQ7DtAgDMu9dkvP/60h2z0NYkMCclMTfz9ij71Bz5hfH7iPY4wE8pGpxBtFvBDxSB8252NvZbIuEKt5MKCNtzo3QKo3wiJgLaJjIArjBKjS1jlg6EpXz50h9KoqkKrABiicgi08vz5CY7kl8Eyouoyq88jz75mkMBEYRsZnQ7kpI8EW69mPq7148q2HM6BQ98EDmAiPepmV+k2ito17e9iL69tMO4zDdujccOztv4RBl+Ux0JsnMOyrru1LDurcBatnbhvqu4RbM935Op36//fAiMfeWIiOdAnbwuE2O/ikdZp5jhiowQDJYixowchkc5iF+T84xA718G4oD3NUQ0wIzQio+oY+r/8Gy9/q3EE6385WxllGH+iUMYgIx2CDg2CGH4I9HTCu+3fkL8sEJABvJb52M40q08bgMYPz0ahMAwu8IohhWELrRnft+3ufuzZ5Qv8ogrDIkUSqO09gIsUzwCRIEHDShMWAAAgIEIFQ4AKCBBQgQADQxAPBDhooUDEwxMOHAAgQEIDRCCdAhRIkIEEipEaIDgQYUCDQQ2iBCT4YSWBhBMeFBgQQUDFx3yPMCggIUFQCVQQKiQoYMIFiggODkBws8FK1vSNGCg/4CDCRQYCL0olmyBoToj8PQJ9GaFCggVKEB4F29evXv59vX7F3BfsAIIFzZ8GHFiwiEUN3b8GHJkyZMhozlDGXNmzZmtFPD8GbSEBgwCl8bbFCEFCWCrgkXwGmxJq7LvqgXrQAJWBCZ37wbQG8JrkgBM2i5w1/fuAhNeWzgO4KfL5CAbqn0wYUKBDGp9qwXQFCjthMdjqy1u9PcB4+mhYz/eHX3v6gaiD69rGn9+/fvHb3bM2L8ABRyQwAINLPCHz2TgIQQifADNo4P420sRgX4yAAAIZpLqAPpiA8ACCCSEaj6wlqpAgt7Su06kj3RqYC7irFpPJQp2WskAC5xD6P8BniTY6Mb5MFJvO/QwcoCmCe4iUSqqZhzqSQRsbCsCiI6DiIEhr5QAqbWCLKrHleiya8IyzdxvsANf6OPANt18E844I+NhBCdmMMwKJ0AALasYzVTglY9IS6ghABzQaLRCDx2OUJKOYqChBg5ogCKSKDo0xIaGOuopRxmAFLkfMZzoAKUKldQCB0jFkCLiGBhK0gyOanUoBhyYCS9YAYA0VVcN8HSlDgkdatcOYW0I0lpXnQjDWUtVFYD7zpyWWr/SNJAEEuTclttuvTVwhh+KkOGzKhuAdj9pqwWsI+bQLc23dTPgy6Z38Yt33b1UUCHffqu9tsBsvx2YwBteIBj/4QChcBBCpfQzwQR/JfZ33oktvhhjNAtoU+CEPabM4I9FxowHJ57gs8d+GcCXrw/x4lRiTr3Tr+KMbb4Z56c2PrDjkX1OLOSfhX4s3HHLpeBcag+AIAJVO+xwAWQPiHpXjV4twEZNLbiLVweSHS5qYSmdFACGjmINKUkNoDpHwCLOed194Z67P561HRrvoPHeWzEojHjwMwQsGHTCkUY6KSIAKCiIorBcWhoppZhyytCpWqvpKQNk2ooll8yKIPJbUUJqAdTotlnd020GmMA1+RZa79dlN4zOkz/z6aDSpcwgBXYFYq6oDwuwCizXXivqOwrCG288lydijruGdrsu/zvk1wNPQtUvTl37i1knEMDZPw7EDfHNx1Nc0CKI4LM8KAGsoAN+6jK2xSdonEP6ADgyybuavPw0LOHOlBTykeMcaT39c1v3ysQ9BkrsewMK3/koWEGPzcBv5AJNAQrlFwuMamqPCmGxqHYostXqVowqVqpAxbVJHSVYGDoWoSD1qYakMDA1e2B+HLjDfEVQQBO04BCJ6K0ibHA5U8OLA76yrnrth2WAeSJgdOjD0vTQitQCon96VkQvftFNTkDiZ7KyNvYVIALZy+K0qrhGv6Sgd2784c6wdTcwxol8dzSf7QpwiW+IS4NIhAC1XoIANcZsNi7cSwach5co7sUkcv+UJH62uJku6rFNscMk36AwAiic4TKE8RvgQEO4MjFgLEiqgAVIYjbSvLBZavuaCV+pNuIM5VcO+IijOAiAqPWKkeYhzS8dABNWlk1QbPsgSbr2tUk+M1d0DJgdN3kgTVaTgjMYo2jspZ/kvCUoQ5EIB52DlFLNpCZSskDTyFkApPwIJGURCSttAwEUOYUFYKkABSAgknv2RCufI11TQPK/kGAOmtCspGYuic0BXdOh5juighpmyntJbz7UO4531MJR9SCEo8UrindAspUJYCQ2F3nNA3Q2HpXCBD4a/Y3yoBSb4j3nYhBL6JkWmpmGRtQ/EAWq7GZgBBnIwAgzyBP/H5czOEoGZ2VCMqBDdMTOqsqkRuu8VVVv1SzB9RMCUyuAUDy3tea1pqzw0dJECjDIglruoBnD4k5N09PMCHGomxFqXj/2U8XkaaKemYBT2SWoVp3thQ55gMwWa0OE0FKxnOJULnX0QVIVS1gr7BWkOnTYVyX2lglh5rNauD0y0ZU/dsUMXvmKGTccorVD86tjigahpJlpZsjzS27Thdq8zNW3f1EtZVgbW+MScbaQqe1nuJkXi/qwjXQFbnAFI00CnWEQx9XuF5MrmaWG5lwL0NBDuinF13ApkhNyXs3S25f2am+61N3LcCXT3e0i5rX37Ss1BfRdz6wPNJTDz0Za//QrznbIlV+D0eCIqTNlaSRVIGlAqlypzF+t0GudhZtO5UtJ6w7IvvotzF5FLKcQYyZPpCyXflTqzoLmKI2fA8tAejIpe5pOn/w0QB3ueZGMCHRyb3XSjFXYYTfSNzInFjGJS+zFBG3wAc/1C4EtYpUFuKQ92fmQb17KUuaB5QB5WClv5OeemZonrjc1skI/LCAlb+YHI5AzFAY2ggIwpgAgEIAVQnAnyOzpYI0JQQFGkJk8NzlhMwhkw8qrl6VthAIFHYsBsmTALWuqrA5uTR4WTOa10sStCDBoI9e8RiRD5s2a2dMTHkSEb9mZMSHggQBgHRlA/4fQd501ohHGA//AFQEKgX1IkfWyKZIY+CPGemELW4XZUfFqsx/5iqW+AlphXbiZHcwZHEsdmFM/Bg132Nae+uwZARTVM0W4EwiIoKcZEIFcPviBAH7woCfMmgfsPhkI7mQ7edP6zgJgt68L8IR2g2DWROD3YfYEjAL4YNboLoC6B12Efd+JCJ6RgauNoGeBG0HgrhYAvCd+px+A4AdGmLd2QUmwcPExAhQYFan81G2Jxbfb335McQ1Ebm3KQADjgoIYXe0ZEIBAjCMIgRN+wIOJh8AHQB+0D0ZwMicIwAghgELUAY5nEFhhTyqHQgGIoE09hwDts97TD8b+hKDLYOhkn3rVC3B1T4b/YE88yDgUBl10PSd97EUAuA9Qvt1UG8gKIyBlWLMjWJtPDOel1vl/xl3wBxW6ADI4+qEPLYCx5zmptYb1oAtNelrzsesCOHStBeADeRdg3p/R854IQ/vMbx4Epjc9FPbkmRB0xggZt4LqZ78z2rPe8PzttVHHaFbAbOU1NQ8MC/LySDlGfs2TF3TljaB0wsjAB2iXNfEJM4MQ0L0IYqRzxhmUa9InfQbHD/jqAz7yzAMdMbQXwBOADn7xt7/0CM3piiDxAo7VfMDtyO+I+g3okE+7Dg9O6m2DJKA0iucB0kjaJmKVwubYKMUCMGFZKCJsZq5RRKvZXOmWhIVXkMVq/36l2fgD+4xM+xIj3CpvgjIOBEbACASv86puBDKOCKxABp5gBIZQAHSP0MSoCEgu9Q5NCa+uMwoA5PKP0I7I1XBQB4sACUfA6YjwQRhDjGCPMA4t8IAw9e4LAuHEzjYoK6QsmuijnzQHKGpMc+bJxyJAFoCkLXbjKzbnKRbCI3xsVD4HcZpmKpxDKiQlrFCqgU7r8eYrAetoWxRu1wpDXEAA2EKOMHig45BuEzuu7AQg3+ZtFEcOBIyg4+gN4TSxqHKQMB6kEg2DCJbBGVyRMC4R2EqxFE9uCVcx/hZOEz2vCDxRFWPxuNLwTYRQQQLpfqDFhEZkeCRgARoAetDDpP+GxCoQoA2mYzeoEQFmxiSoI5GybKO+oqOaZ3he4732Q24esWU8ThJLrDMiETGYjNcOBA3QAG848RRnLdiOxiY+49hwCiJkAj1CpEV4ow300CgKcmagIhDHca2MI0s0wnE6ZLHG0R37xQDgcZqa7OToTDHs8R7vawZMZozcqbQgRVIYoFUw5YMurAEmIQQpbdmW5IRUaIZEiFB+wlAQ5cI2EoI8kkCQMbZIsiT1ixORiAQf5mJS5HCEcnWIEsSULykFACmv8r5UDI0o4JCk8rccESw7sk2wSysPIyvPMjNeINAs6MmQaLDQpcGqL/qMLAY7jCzbhOfUki/jcYh4Lwf/zc8IAqwCaOK/DikpPgoFV9CXnsWN7lK+8vJA9rIvKzNAjHJoXi4lNRJrciMDPqdJnMOfTCeLIJO6JNNAKNMyVxMzMHNvrIDkNigvsGYmMkCjbIqDImClHlMspRI1i9Iqk9IyWPMjI8rpNsgra0Oc+EBLKlI9FGLBeBMsc4Uq3Sw4SzItibMxXPN1em+D4pJTLKASZmgofJKzmnI6j6w6L/M67zE7tTMx2HKoZmAEjo7vmM8zbAQhqggqiS09J+k3q7Iy3xM+EU0zPSOs+OA/JW89uag9eY1AC5TXYDOQEOC2UKsd0zNArXNA21JCJfQf/ys5pas3hXJDg6gyh/ND/zUjHyfUCRavV6DJNIPrRANENVf0Q7kTjAItBPATa9CzNEt0I2vUP24URwtUR78oAwwjXLwTAmJ0jWbUt4hUM1znSK/0MJLUi5YUMShURN0QvoTUHanUpx4U0SI0R820tbg0McKFlFbDirjtP8m0NdW0xNBUQrW0iNhU0ALrfhbUiuiUMvQUm/C0QFsO0fjUMby0rQ6g0QA1ZwR1Mgi1mgwVS+/rBiiDPgEHI8AUUjNGUuvLTpfMQy/VVBFDAvPTUy2GwzS0QTfDSvkyj06VVhMD7z5D5uBGSlErVCXDSGuVLyl1u0IgsEICZ3aVrno1Mn4VWM9SWCsoUwfECgbTM/+MVa7E9BGVFTKYtVmv8lkpSFEDZFpvxz/zBVl3Slsdowb7cla7NUtHdajCVUDoU4Oi8uaw9fHSdTvhFVNL1V0F4FvPR14HhF4RtFzPpFWnU18VI2DByFK1s2HFZ2AJpGDb6mA/NbVelaH4dbse9l8damILpGLtFWPNpAI0tkw79GOdtVtOEnBItmT34wBQtk5VdmVvVjFSFWb3Q07Tc2bLMrv6Mr9wFlFx1hJf9mIB41wDgwEOwgAe9WJ+Vi+NdjUjli91Nmnxoq3SY2kBgzem0ctwRmonk2ot02plJ2S5BWsDwzNe4gAU4B2kBF2kxDcsYCWmcXEkZSXK4m63AiT/KO01KECXslG8bgJpfgNI82VsC8QshRa2cPZsXydtu2Vtd+siPMIVIAA3BGysluIBbuxH+okmKMJEEHKsUsQBmCisziMc2UKXMstfFhc4bfZmI5dvJtdbKncvuIODwjGROAoBVldvZUMgyOMcQaIlPvcjnsQkkEJKiAN2+0V2BbQvPZY1bXdvcPfV6tU/jeMAsOEmFqI2VGMCGAACKOABIo14fgQQc6NHjkPCMAIbi8ImSOIbvzJ2aXZQOVa7rHc1WzRR92Zki+xpE4I0mMiUZmLmvsJrJGQBKO0pDoKJdiV3FmABPsVpVcWCFUdJMmZ6ObR6/bVs70t7Xa4IEVT6//7CkGyGJWzmg9mTdkdYxERYaCrWWCtAHaHWHV/YP9aVL1VUhoNYuU54OUADAXpohfViK55PIxmIh4tUiM9SPqN4MioWNDahRG0DWh54PCY4ISiNiVJ3bQqFixPCi+fmiTeDW6mYr7AXb2j4dbRpg/Ygi1WjacYiRVwj5hZgsRbCJWwiNq4jNxwCeOgmjTVjjdl4qNz4WxhE/B5Z/CYBkieZkivZkiFZH85BzjaZkzvZk+Vs0QrgFbIYQzhoeLQMfkUNJDBCNZqiPEpZpE7nkDHDh9WSGODhknNZl3eZkp3gk38ZmINZmIH56IrZmI8ZmY85EiIhmZvZmYuZK1NSmv+nmZqpOTheA5uzGQH0QJu72Zu/GZy9OdnGmZzLmZzPaCZ6SC2WQqSEIpWXRizECihi40mXoktU5wCobpj3uROX+Zn/GaAD2pirmaAL2qALIAHCWaEXmqG9OdLMGaIjWqInGqKF4isuGqMzWqMvGg7gYKM/GqQvGn8nKbok6RmjpURXAgHmoiKkZIkbIMogQjQUxymWWHfmIonppgFWl6IpOiY7OqSDWqiHGqN1GG5Y4G1i9ma6lrpKWqnliCfMFV+VGqmf+mZ6tmSd2qqzKKrXhakfsaq3WqwvRqvH+oG6ulq++vHC2qzb2qwTdiyb2ExMwA7c2q7vuq3VGqrl2kz/Ehev/7pMsBqwo3Sqc46vy8SvB1uxTUOvpavDGtvUDlu98DoF+GWx/6SwpbKsJwmyuVqy0yWzMZatLxsGQ3sjN1uSOjtQP1s/VLvDRpu0W9u03RG15UiwfZO1eWi2ARW2Yxs/XJukfft00JpagJu6elu4AwOuP7W2k/uHcvu3d3tBkdu5AVu6qxuxoZuxr1s/mpYvLviMGegNAAG7y3unbttEtbuu9mN4QIS3JiJs72IdVWJq+DqnzRu/85q7eVW9K5C93UlDvEoamSYm1JE48HgBHKAqBHc3bLoqzCpJ/FbUFhxJFsdGbjj6/Da+87u495vDS3tBiVuL2FsCIEAC/9RipyviR6zCVgxyI76jKSiwKfjwOJ40IZSTqgxANezQnjgoRUhnKbxipPtivD+8L4xbjqhPvpC8e0QcYetaP8aqLcxDeE1CedFMRrhMHV95NmH5N3bjaZg3rhzio/SDuo2cydeouQk7xPtbaaV7ZtQiSxaLAtaJIN5iKBZRLuQXhzvkOK7jAASsSu65JeRHI8QcACYAIjgCp/DjzD88zbNozYO0zaUaTaClgL9YVdbGgJ+2aSF4VyAYvJ8t00M9jB+ribzb00cEQ8LbNB6dwyPdiibdipY7vS39rmE9v2Uduox8Ypwcs7vtAOYialaVL3K6tweCWgxJ2ftigpd4I/8zNKt9HYJuYpwx2tj3gtf9BY0UR84PwrsfGNMz2IzVgokMQB7e4IITHCEu5WkzndO/eEla/WkrGMXf/dS/gjS8ooXE3ZeadsipvV+SWuD/paB1E5uv/Suyh65NgwF0JNvhplED3HcBnSwMV6Q66lfkB3R6IolpPHjLF+MVfZBJntEl4AEAPXpcAwIMoo8ZgoMC2Sc6PjjGquAHe9vhxgB6gAN6ngOyQAOCXgNg4KBvhzngyVi+UiY+I4W7x5Sfs+J1kyF+F5bX+QG+ET2Qw89dajaEp8xNGaRgmca7eJW3nsvlgz2oS9pv3l9yPlI1IADiXu7nXu5bQATuvgt8Huj/g54JDPqaL0J9skgtUoXKW/orfmKnvcacDJI7JKCrWGbswSLxr8aCO6ryaQIhnvTxzZ6DNNcjboOeU2UkpmPJPZzt/8LtccYA4J7uW9/1Xz/uRQALRMAGel4I+L6ax4x0tefjExwiUt5uVxpE9tZtDcmQeIIC/KAdmp1HGsCmrcJuuQSHhX/6KwDakZ/Znd/KEIABZPpcUsSmU6QhlJ35fSv1tYfWfej8V4f1Yd/9X38K5sD97772DVr34923dB2/1/90ACIDgIEECxo8iDChwoUMCypQ0DCixIkUKRrQECCjxo0cO3oMcOHCx45ZCpgsIESECA4czGhgcjLmyQgI/xAcOFDBgIOKPHsaZGHCp9ChRIsSfWg0qVKKApc6bYj0qdSiF0datRry6kYsGjRwGOlCJUuXMGTKnICAwoEGBhhEdEABgQQDUwEArYs3r9Soevv2bOr3qQoVgQsjrKo1scasiht7bCGiC4csXc3GhJB2bduCDibEpCv1ruHRpA/yLY16IODUrFtLROz4KuPYtEeKbamhrOUCmClQkClhqmifC9wWZLDAtfLlrVczf+4adm2Ps6dbtwpEBBbcundHOGDBQHKlbwAN/N3gIILxCB+kL9jgAfT59OuzHmx/qfTrGq/Q4Q9gY9lNtttJmD1wwGZEOVAABRMAsIAECFjQQP8BEyxQQU0VLGDTA+65B4B78cGVVn4mnojiURClONR+AYoQYIyNCXFSD5IJkdtuE0iAE3sTWQABAwVwiIABdBXQVgEVHBCBAUhyeIADNlEAwAE2NVkBi3iZEJSWXtZ12pcTuQggjDKeedVKNrjQUWQc4NhdTDsmuNNAcEUQAQUOlAfABJhF8ECEEDyIpJM3JVjAQDYBYEEEyVkJ1wQRGCemUmFW6lOXYl6K6UIMoukfmqICGJYNHLxkFgQ8IhCTBEAtoKQBTFLwgAQPRiABA3MWmSgANjWAgAMQLGClBbRO2mlSnCY7kXNaLsvsQQWgWd2o1vKnnRA9FFjANSYwAJr/A20ZORC4Oy3QlrgDFacTAMghB4CRdUY7FLT0LuQsi/beC8C0Z1Z7bcDY2lCSZWmFxy9z+yZsUL4pLkyvvzICLHDF1sF0EgxxmqQqTpQybBjEIAPg8MiYShwjxRav7BgQusEAxBrqrGTGtjLR5J6PUj1QE09WNoTkQD9PtOhCSDJwQLy9FpRCCiY3VPLTX6IcoMosX52YSmxOcQVH2lFm2QQUhDdvUrBaEG8DaiPNANINHMCAAzelZ0ADSNcNwNvpOWCBBUFXicDbDsi9VtqC533ABGtlGWUFbKktK9IFwJ10AxX0DQDfFsAtNUIsdB4t1QBOMQfWpl/bgmSoytRx/wUfCxU0kw80uKOTFVAQZE4QbM7rWgfMBQGwFDgJGpOJ56r75t/NOYEBiluAQAUFALs5BIjWXWiiCCgeAfTD/w16tFyGL3qZp58fcFhv2hwTzg3oPFHsCPQrK69KcyjpTfb7ilngQf/9Myvh7zsBrEnSbAKrB/imAEibH/2cpDRfHfAA/wNN+JglMmaVD1vo62DFREAwDRhsbBYcSAU8M4EsEaRCVPoZkqxEvLgAyQDWg2GvEmeACmSIAtIr3vyKBQEa6g9wOLQeACDAQN4AbiDZy4n2JggBHoLvgp3KYLI2eB0zeXCLHlkDFWKUulNtzEJqkV5M2PO2pOENbnVzUv/fBte38NQNaQRZEtzcxrm0pU1zcqRbA/hIF8cxKkt4q5JbNkdHtuTNAJTQht9KGL4VbUqSUsPidKhACC5qkiNeHJX6zICx3cgnIhCs1AHiAIFRUpFkmLJipyxZG6tt8nyd/CAWhBBKA/GoXSBzJb+iZiJfVgqWtJHlLE1Xy5XZgFu82WXZkiVMegEzP+MDHTFjY8xjXi2ZK6ORSYQQABCCjXUSQFgVKbnKaa6yPtd0TDa1uTJurgwyQPBItth3ErG970vVXCcr/emldjbmnfAsKMuylcsC0IROAH1WQ7UkUMVg0qAUneUnNzYB97zuoRx1StPIJyotVnSkmmwBwfD/yRsK/LGjLFUWOk0WUcWIlKQs4xpNP6I+EcrpAPBDTTRbmpqfBjSkN8WaPIvaJg7gM5UqDOpLL/i5SgkVotQSCVLjaYurasUFNhBCd3C1UtJMtVPqrM9YUxRTrRBUq/xZq1a7kIVcTmijeTlrpcpKH7ueKK2ysSpbA+bWvwIBC/jMaE/38tTw4XU++LFmVf8qsMBCNgAmNcNlHtDUqej1S4sFKmn4ihW/TlZUV+jaaGnjgi54dSY8nEpj/dlZzxoGtCOR7GlvWzHVhhKszyRKcXwCL6PwcjSaki10aGsb3Cr3mECIa6vCypMGIDECwEpaT4ZWlCkaNyGbzQ9yPzLT/+Vep7Ti5c9g8SkB6EqkAGgDFwLnxyEoeahWGNIQ4NBCECvlSoFpcUCEFpWh6DFKLkLimSq3a5rEMuy79ixv1UTr4Om0gLBysgBd22OSC9kEgsR7UlrEoyQmSVduDnQSWxiAgAcIC0g4UVKIqQsBB7Rtcj00THG91F37MJgjoYrwdWzr445MuLAWNsiSmho3A9Rkw4nqsKLUOLlD/dCBgFPSomzSoLlFeYhMPBIk9RJbhSk4YTveCJCDDBIIo9k6Q66wWzyTYSaihbo2YUAEJuCZUhZtVwXGb7x4FIEAP2BSD1Dc8PgMqO952TBhXk6O2fnYNRdTzZJmM4XzKRO0if+rXRmghLt0Aup1UQpdbgFXcCG0mRTzElzjIfVAxBOvnQzXL41WzqPpU+bFULrSoeX1mdpsFioZpLsgQlGtEVyXXGfkzEGewhR8LaoWWFZOmQXArY2N7OcoO83Q7jb6WjDGPFUboMfO9lO2TTpvq9t0QMCRGeAaylQe1tzKeW0librufJ+vud2ZQJHp/ZxrHxff+u6IswseMNU+F+COHjO/th1OhHeE2RLXijWQoVOFUmDeCXN4fgSubTSlu+K6Jrm1stICDsTbAr1NWLlZA3LmbJviEaa5yakjWhGs1iTDM9nLnQrSf+1a3za/OUcAxlX27a7lClEy2gy5EOwyGlP/H3Ws0I1edKOX/CMtyEJ3eh4RW0VAaRRgwOZYrkMIhSc9Z2e6VH7OcKLMfOhar3ttDn4VG2R8Au9xV98+JqQFUFdILGeLBCTQGecRa36GDw6t486audt98ldrt26+U6GTNLVRx6OfA2yFGXdND3Cf9xOV9RJVyJdm2z2mvOsr5gIsJNQkYx9Ix2YnJERVQEKJv5AAlSQhgPfz3mgKL8Kp8MXXm07vZnGL3IzD0yUxQG+Wy9IC1o44tQE85suBuPELnvW6I986Zum76n3CfeWw/j83D7/Wz1ywy5jfRKn/UvpdI/n20135fb0OV7zCAZcXJScCd6Vxf62Rfybnfli3/3+OwVUY8x0XthwFKFYeFzGRpoANyH8fsYA2EEplVx8USFw3BlMYSHLjt4GTZi0ikHEgCB0ieH7xY4IpSIMbgYIrmHFF8hwwGIMRgW6lU4NBiDUt4E0FoIOs8VskWBGzlhdMSBGmxnE6RnBCSIUWQ4QncYQMUUra1RMgUmxyZ0FBUzRJsR6+4iNV1xC5J3Us4n0MWIXaRIS6wXda2CtIolIhYgH8pSf/lTQSIgHJAT0SUAEREDzukYd5s3ESYl0AEGBJ4yGH51+HBz5iCB7y0QAqdXh/SCJ68ogBpicOwDMqZSEcomTJgQB7AAv2NRCPuHh/+BsIMj8B5jiWqGJxof8nAfZlnzWFFbeAN4d3V+MCAcgx81cQTnISshJjSJJiK7Z0wYMcEjJibXNliNIZB2A90jMecdNDciFEu0M/BBETiKIrN/Egh0cBwOM96SJE5xgv36iMmBUBGfBiBPFhM3R4EGQlQrIkY6cWwXKONOQ3DwBrCIgmE6V/b9h/pxOMurE7EsAbi7iFSeIgEiRBYkgBeWJAVDaNAFAHFCQkapFHD2A9yjhBFQSOdLEoUVQAJAY4BpQgAAYo1jOGFSRdvqEIW0aPSWONc4OPvXMTENI9vmITCZIhgIJ/MyhxvZiBHbSQZvF0EQkADpkeNTFoDFBog+YkhYYAdqZABmArSpb/NLKAKyFiaKDhILMDlhJ0lpOIkknjNy1kPYE2iAfwANBTOd/xHXM5P7giJHSBJwugAJewKjnpLoByAN+zRLuyADEWOHNZl4qTUUd5dQeJkLWlgQLjAvEXZ5kDGu3CJIoikHWCLjsBha+WHOLyLgCACQrCasVoLr/1W+MyL+0Sm0MCOAqyaRBiHAvAm863GeZCm3TxEK4magQhL+oSXKT2W+qSm60pmRNzmdD2i5U5cdEZMCJQfgkxNqtIjBXBgwRhLAMRH4JBGFYHndS5gUoZGy1gGcGTF9/Zg0aDlOhpd+TFRctkEj0gjLzRnUkBn/GZENtmkPRJoJipEhnRlLyR/4sASlXFZ3TTWaAjlaBZ2FEHGHm7mJTWGaFcNKELukoWmhptSJkbqp5oEoxYGIUSoYQPY4GhM5/gp6E0WKLRVoQuKBT/qRcgihoJSHIzinA+SqMnYaM8gaN11aIa9KJEF6MpCKSj0gI69R1uVxA841/z4zCK9HFHekVJmm/2SaJLukksSHuLqBCsMhdD0gbuEiV6wwCYkUM3UWrgUTmXYyQshzd1wzcJwqBMxKUb+qNgOksigDHuWaa/4ZFIAiSNIiudUXY5wSQO0D1+4ys7AijdU0ASYgBPx6A86qed2kEemGGBhBMFMZQmAQDbgDvvg0TBsiiFlmdN9kQQNJRT1v8AEVAABxafImpyXuqpt7WftrqZEiQsiQIBeOIAjlMhHJIrBJREmxOrT8R5aGEBFTBodTF8T6OrPQqovVpQmemU4kkXsuIrt6qmekosRuI78UKXiXJilUMXfeM4spJHiBV0Z/J9StqpvIpbHCATwnYQtiqBBiEhhNoaOrp6oMJ+SwkZbGIdYdECWCMC9bSwHDGxW9SkWMOv8ocQ/NBKWvpKfRojlPEVAaABWTBSWcGv95o1BTCyLFMAGJGyAcABNpARMWux22pQ4GYWFPpPk1SvKYOziqFTMPKyGpEdDJsYDtsmDwsZV5EdD5sRkAG1JWezKlFPaRKxGYGdHNC0GxH/FkirtGAhAmwCBFcbANmhRUW7EWpLsSIwteE0thZzsVjTbhpgBkCwnzZapHhhsLo4mQIjQjDQAwFQtC6QcTSrtkUrQl4HQicBTiRbANsCAxlrsjGbsi3APhxguCexHQUAIykbsxk3uNhZMxihEaIbTpGbn2GhugUAAw+LnyiRuqVLuExQFj3gTV0gsxnzsEWbshm3Ep4bAPEHTiLQHSoLtJLmAt70HapBdU5jnslbMSKEBSxbtCUBBC7ABExAuKaruAWQBRwABL5bALorQqbysoI6LZbrufz6FQNSAFgQTuj7ue0rvF0QFiKkEpE7sxuBv2K6v+DErzaAnRqgcyzr/wLk2wXYqZ+IywRdYFlZ0AVF67bNxbLdu7sRG7ljm7ITLL+W9aT3+7YnF7RFJaa8UQHldmqnhhC/9Wot54QdxanWIkIB0ANlgREZZxIYjME1nLpfsbWQ+8NCzL4RqxtMAAQ+XLPCC7rCWxLb67lBzBFPDBP7C8QsG8Rbm8VYfMEZQb5EixE2oDHb8hVfzMNNHBONaxIagLTXAqFrBqoFoAcBKzQnoalCQ2XjWaaLWIbS4qEN9YMWU8PYWbQ0crW9ywQuwJ457C/sCU7LRLODfME1zK/ySyMRCxkloQGGHADqE78BcMkpi52VG8VdrBGjnMFBXL0EfMFb68gBAMlSjP/BMVu0kTvEZqy2KbtM8tvJDgvBpoyeJ2oSA6gQP3OOKNZfiXOOCxAfUBI4gJMrNvF58QWeBIYkmwiKtYJ449nMEnLHIJOt1+LDloURLvOy2wK5rvu9GkEjudEDbCLJXyHJJlEWwasB22IDLgMDucEBhKzOweu2GjO0shy1Am0S+8sEIvTOW/wV7Sy4rNuyuIwR25IjZQyzwgsTBpyyLrAtPaC/ufESMLOhIYzCxXwSfyQuNVSOq2I7FGRibZFic/g30diX7CgBcQE8Q3QAfuAHRfLHLuqgFWMqUdu/nWwq4tvJWIAFKUezQ60RkrEmGTHUKQcjTr0SC8y1XMUSV6v/1VjAJle9DrwAGVx7thyABZLRAlTdEXh71lybctvh1ZTVz3JtJlDNJmpdszS7Eg/bv8HYz3Pdv3st15or2AEgGRyguxNm1iNcoF2AMcgzqvkVi0oSkzptE/bTk1bGKlkCQFRGki05QQGkB5sgAYNCfPbqhn56g+omzHKSXzShKrVqPDsZaDakNF7JJBlyExHAIKDBlYo2l4E2jdKDABCgB61QKw+CrSIHhEvpp3OrTWugEZibaeViJK3Wm8jxmwvAnHTharFpLsWYHO1iarpp3r1JCs1ALqctvc79peuWARuRsUKapT/7YKn93uoW3xox3xwzbmJm3wAC3dxKUwM+/0v7XdBmgXj0ca0l+LcEnqHwzRF1awbBq1D/vacUMcMQnm+rDW0I/hFAYDMLnuE9sX5G5+EcvmbJdxUZG2glzhPhHOEqfnMibhIkXrAeezIY+qc0rnUujuEho+PDxOMw2qlvXHc23iBSGiI1oSdr+I1dtijzyl1DLiYbbuTPXcJ/BeKNUTBBtBAfZj14gzSbY0iagyRs4SQ8lDRI80x9OxpYjq9aLuG1ob6TU6ZXUj+Q2jeJooyKVmfsBSuZCgEJFuBtteXileL0aeCb1OUO6E3+hkJNVRN4dpuwSj8VtChBc9MESxBwPlsg6+Nr1uia9Oix0QVjNB7STEBbyV4URP8/abGNSTM5x2qsB2Fvy/3go+5tpc5Fp76eKDVKiiQrgiQrs2NIeDR9ouoW5PpQcs7rkqavvgbssdHfzp4QA9ufB+EkdNw5Mt7j0U55sXvjfpHrDo7aIyrudleEJhEsOWrlU1Pkc77uk0dPYqxQP10UoF4YAppJ6l6gvm6xo6LkZJoQmzYe7QoVK0JHS2g3Bo9rot5tAi9pFN9B1c4fy+vuUuokxT0By15KpEqmURHyY8IWSyOFuy5xSI6eFo8+GA8g+N4kTdcracFkABAX8kaIaoNnfqAAIskq9IhnQTKNTCIBtW0/IjmH8wHt9V5zia5VMA8gSl5oFpJZpWQlNz//fb9BkXlCQdOwkiG/KIpT9PPDM7aNK/82cCrv9Gjm8ucj9aTS7ibBHhDUplaCKAAAKJK6KN9hJNIjLksz9tAjH4rzM7Vi28SyIxHP9m3vY29/OnEfIHOvSsZolDdf2kE/aDy/PYIS9IqCZ8FSIRBQQ5gxLLZt+tt+oWcyoCTH8tQ57bwm3RZz7bjqFGNoEFCOIuCe5Y6fguReAI5HFA2+SAlRSEMV1O7t+xs49xPA5At/6BwE8AQa+wRKT6muUCm6EPweGE2vbpD/9Os2++xmM99MEdzvF97f61D/fuyPVJLvSd6kJz2hAHDQcupyL+rfbdVPnQBx4UIAggUNHkSY/1DhQoYNHT4smAHiRIoEsRQoMIFBhQMVAHz8WAFCgQgHQH5UEGfByQUIABgocFImgpUybd7EmVPnzpwFKjoU+FPoUKJFjR5FmlQpxKBLnT5FKBEqRREwMF6dANJByZcFDCCggOCACZUVECAwQKEA2gIHEDQAYBZBhQYZF8j1+OCBBAsHJDBo8ABA4AUSEFjgmVixTJ9Lm06FHFnyZMpPH1fGDFFq5oQtelzFiLgrSLEFKiwogBrmAwMLYHblWIBBatSzDcxeUBuBhAOmIRxwC8DtWQMGFh9P3FjpZc7NK1654lz69ADMqTvffJ0D6AIUPtoGsLWuca9ezUZgHfM1zP/XAMoXj+n+64HXYoO7LQwhK3L+OJUnvYKO6wZcyDoCD0QwQaIGInA70Ez6qDcEInCpOwmy8mqCAyZ4ALX0RptAggsBiOCvEEcUq76O1oIArL326y9GkP5LSgQFETTwRh135BHBFqy6KoKaAGCgtY8KaMC4FOBwoMiaXHPAuCg/Ku47Axx4yTgAFmBgSi635HKBKLWUsUwakbKxx+lyVLNNN9+ECgghNDDjMyRvogklBcrks0/+zjQqQDg5Y3PQNqmgwlBFhXLBDIy8y0mBPf2ktFL/nCp00eUY1BTOTDvVjEcHEcDyJkktRTVVQIv6FNSiEHX1zVZjXSi7G7uwCoL/IU86NVVf/Vx1QU5pJbZYpoY1NtQegWCCJLhk6vVXaWMMdqhZk8UW1GuztVVHFzTASLCTVFBhWnP/xBTZbNctdltsu90xC4xIzYkB4Mg8N98ZnZpiDnaNcvffyKaYQuCG4N3Rhlx3BQkmCh6IIDwjo3RgJTGJrFLfPqsdKk2Dfwr4Y5FH/olZjJ49SQJIm0SPQ5gQYBEC4fyCUWNqn/KY5IdC1rlnnxFq9Ko8JCkVAXGFc4m9mFKMqQIKJojP5pudyvlnhXi2Ouuem71Kgo8aiKABsxqAwAELIFDxtQIsqCBqqdFdql+tC1R3bqgIzjpRRbkroNQGzkLMLQlyc+mB/wZaAsACsFx6uz+Of8LbboSwlhwi6PJelO9SG7eZb88/Bz100UcnvXTTr4JBA9VXZ71111+HPXbZZ6e9dttvxz133XfnHfYsOAA+eOGHJ754449HPnnll2ceeO5k5jx66affqcjirsc+e+235757778HP3zxxye/fPPPR5974NZnv33334c/fvnnp79++9uPACMhqee/f///B2AABThAARZncwREYAIVuEAGNtCBD4RgBCU4QQpW0IIXxGAGNbhBDnbQgx8EYQhFOEISltCEJ0RhClW4Qha20IUvhGEMZThDGtbQhjfEYQ51uEMe9tCHPwRiEIU4RCIW0YhHRGISlQW4RBoGBAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram depicting the grade of hepatic encephalopathy and the clinical features associated with advancing stages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Conn HO, Lieberthal MM. The hepatic coma syndromes and lactulose. Lippincott Williams &amp; Wilkins, Baltimore 1979.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12883=[""].join("\n");
var outline_f12_37_12883=null;
var title_f12_37_12884="Positive patch test reactions";
var content_f12_37_12884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76954%7EPEDS%2F74380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76954%7EPEDS%2F74380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Positive patch test reactions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 166px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    From left to right: +++ reaction; ++ reaction (note the microvesicles); + reaction; +/- reaction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Panel 1 reproduced with permission from: DermNet NZ. For more information, visit",
"     <a href=\"file://dermnetnz.org\" target=\"_blank\">",
"      file://dermnetnz.org",
"     </a>",
"     . Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Positive patch tests",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Positive epicutaneous (patch) tests on the back of a patient with allergic contact dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William L Weston, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12884=[""].join("\n");
var outline_f12_37_12884=null;
var title_f12_37_12885="Megestrol acetate: Patient drug information";
var content_f12_37_12885=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Megestrol acetate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     see \"Megestrol acetate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/0/6149?source=see_link\">",
"     see \"Megestrol acetate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Megace&reg;;",
"     </li>",
"     <li>",
"      Megace&reg; ES",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Megestrol&reg;;",
"     </li>",
"     <li>",
"      Megace&reg;;",
"     </li>",
"     <li>",
"      Megace&reg; OS;",
"     </li>",
"     <li>",
"      Nu-Megestrol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691278",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help raise feelings of hunger.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat endometrial or breast cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to megestrol acetate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2807748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There are 2 liquids. Make sure you have the right one.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697732",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for 1 month after stopping this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698160",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Impotence.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take tablet with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10835 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12885=[""].join("\n");
var outline_f12_37_12885=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192314\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192315\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025225\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025227\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025226\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025231\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025232\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025234\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025229\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025230\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025235\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025236\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=related_link\">",
"      Megestrol acetate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/0/6149?source=related_link\">",
"      Megestrol acetate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_37_12886="Rocuronium: Pediatric drug information";
var content_f12_37_12886=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rocuronium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"    see \"Rocuronium: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/52/27459?source=see_link\">",
"    see \"Rocuronium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zemuron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rocuronium Bromide Injection;",
"     </li>",
"     <li>",
"      Zemuron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Neuromuscular Blocker Agent, Nondepolarizing",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant, Paralytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient. In general, the onset of effect is shortened and duration is prolonged as the dose increases. The time to maximum nerve block is longest in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Tracheal intubation, surgical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: I.V.: 0.45-0.6 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance for continued surgical relaxation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 0.075-0.15 mg/kg; dosing interval as determined by monitoring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous I.V. infusion: 7-10",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"      see \"Rocuronium: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose to effect; doses will vary due to interpatient variability. Dosing also dependent on anesthetic technique and age of patient. The manufacturer recommends dosing based on actual body weight in all obese patients; however, may use ideal body weight (IBW) for morbidly obese (BMI &gt;40 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) adult patients (Leykin, 2004); onset time may be slightly delayed using IBW. In general, the onset of effect is shortened and duration is prolonged as the dose increases. The time to maximum nerve block is shortest in infants 1-3 months; the duration of relaxation is shortest in children 2-11 years and longest in infants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Rapid sequence intubation:",
"     </b>",
"     Children, Adolescents, and Adults: I.V.: 0.6-1.2 mg/kg; (Cheng, 2002; Fuchs-Buder, 1996; Mazurek, 1998; Naguib, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Tracheal intubation, surgical:",
"     </b>",
"     Infants, Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Inhaled anesthetic agents prolong the duration of action of rocuronium; use lower end of the dosing range; dosing interval guided by monitoring with a peripheral nerve stimulator.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 0.45-0.6 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M. (Kaplan, 1999):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants &ge;3 months: 1 mg/kg administered as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children 1-6 years: 1.8 mg/kg administered as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance for continued surgical relaxation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants, Children, and Adolescents: 0.075-0.15 mg/kg; repeat as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adults: 0.1-0.2 mg/kg; repeat as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants, Children, and Adolescents: 7-12",
"     <b>",
"      mcg",
"     </b>",
"     /kg/minute; use the lower end of dosing range for infants and upper end for children &gt;2 to &le;11 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adults: 4-16 mcg/kg/minute",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as bromide: 10 mg/mL (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zemuron&reg;: 10 mg/mL (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as bromide [preservative free]: 10 mg/mL (5 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: May be administered undiluted by rapid I.V. injection; for continuous I.V. infusion, dilute with NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or LR to a final concentration of 0.5-1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F7282116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS; do not mix with alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Dexmedetomidine, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), milrinone, palonosetron.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Micafungin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Midazolam, morphine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; intact vials are stable 60 days at room temperature; open vials are stable for 30 days at room temperature. Dilutions up to 5 mg/mL in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, and LR are stable for up to 24 hours at room temperature; do not mix with alkaline solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to general anesthesia, to facilitate endotracheal intubation, and provide skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in all ages); to facilitate rapid sequence intubation (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F219106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zemuron&reg; may be confused with Remeron&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"       - Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"       - Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F219104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, hypotension (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal ECG, anaphylactoid reaction, anaphylaxis, arrhythmia, bronchospasm, injection site edema, hiccups, pruritus, nausea, pulmonary vascular resistance (increased), rash, rhonchi, shock, tachycardia, vomiting, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rocuronium, other neuromuscular blocking agents, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment; consider dosage reduction for severe hepatic disease. Many clinical conditions may potentiate or antagonize neuromuscular blockade, see table. Increased sensitivity in patients with myasthenia gravis, Eaton-Lambert syndrome; resistance to neuromuscular blockade in burn patients (&gt;30% of body) for period of 5-70 days postinjury; resistance to neuromuscular blockade in patients with muscle trauma, denervation, immobilization, infection.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Clinical Conditions Affecting Neuromuscular Blockade",
"     </caption>",
"     <col align=\"left\" width=\"240\">",
"     </col>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Potentiation",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Antagonism",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Acidosis",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Acute intermittent porphyria",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Electrolyte abnormalities",
"        </p>",
"        <p style=\"text-indent:2em;\">",
"         Hypermagnesemia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hypocalcemia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hypokalemia",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         Severe hyponatremia",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Hepatic failure",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Neuromuscular diseases",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Renal failure",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Alkalosis",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Demyelinating lesions",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Diabetes mellitus",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Hypercalcemia",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Peripheral neuropathies",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ventilation must be supported during neuromuscular blockade; rocuronium should only be used by individuals who are experienced in the maintenance of an adequate airway and respiratory support. Rocuronium does not alter consciousness; use in conjunction with adequate sedation or anesthesia. Severe allergic reactions have been reported with neuromuscular-blocking agents including rocuronium; cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions. Some patients may experience prolonged recovery of neuromuscular function after administration (especially after prolonged use); patients should be adequately recovered prior to extubation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F219060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Rocuronium crosses the placenta; umbilical venous plasma levels are ~18% of the maternal concentration following a maternal dose of 0.6 mg/kg  (Abouleish, 1994). The manufacturer does not recommend use for rapid sequence induction during cesarean section.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peripheral nerve stimulator measuring twitch response, heart rate, blood pressure, assisted ventilation status",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nondepolarizing neuromuscular blocking agent which blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &ge;3 months and Children: 30 seconds to 1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1-3.7 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 3-12 months: 40 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1-12 years: 26-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 20-94 minutes (dose-related) (most prolonged in elderly &ge;65 years of age)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.21-0.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.22-0.26 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hepatic dysfunction: 0.53 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Renal dysfunction: 0.34 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alpha elimination: 1-2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Beta elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 3-12 months: 1.3 &plusmn; 0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1 to &lt;3 years: 1.1 &plusmn; 0.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3 to &lt;8 years: 0.8 &plusmn; 0.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 1.4-2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hepatic dysfunction: 4.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Renal dysfunction: 2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily biliary excretion (70%); up to 30% of dose excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Pediatric patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 3 to &lt;12 months: 0.35 L/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1 to &lt;3 years: 0.32 L/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3 to &lt;8 years: 0.44 L/kg/hour",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cheng CA, Aun CST, and Gin T, \"Comparison of Rocuronium and Suxamethonium for Rapid Tracheal Intubation in Children,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2002, 12(2):140-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/37/12886/abstract-text/11882225/pubmed\" id=\"11882225\" target=\"_blank\">",
"        11882225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuchs-Buder T and Tassonyi E, \"Intubating Conditions and Time Course of Rocuronium-Induced Neuromuscular Block in Children,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1996, 77(3):335-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/37/12886/abstract-text/8949805/pubmed\" id=\"8949805\" target=\"_blank\">",
"        8949805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan RF, Uejima T, Lobel G, et al, &ldquo;Intramuscular Rocuronium in Infants and Children: A Multicenter Study to Evaluate Tracheal Intubating Conditions, Onset, and Duration of Action,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1999, 91(3):633-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/37/12886/abstract-text/10485771/pubmed\" id=\"10485771\" target=\"_blank\">",
"        10485771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leykin Y, Pellis T, Lucca M, et al, \"The Pharmacodynamic Effects of Rocuronium When Dosed According to Real Body Weight or Ideal Body Weight in Morbidly Obese Patients,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2004, 99(4):1086-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/37/12886/abstract-text/15385355/pubmed\" id=\"15385355\" target=\"_blank\">",
"        15385355",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin LD, Bratton SL, and O'Rourke PP, &ldquo;Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(7):1358-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/37/12886/abstract-text/10446832/pubmed\" id=\"10446832\" target=\"_blank\">",
"        10446832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mazurek AJ, Rae B, Hann S, et al, \"Rocuronium Versus Succinylcholine: Are They Equally Effective During Rapid-Sequence Induction of Anesthesia?\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1998, 87:1259-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/37/12886/abstract-text/9842809/pubmed\" id=\"9842809\" target=\"_blank\">",
"        9842809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naguib M, Samarkandi AH, Ammar A, et al, \"Comparison of Suxamethonium and Different Combinations of Rocuronium and Mivacurium for Rapid Tracheal Intubation in Children,\"",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1997, 79(4):450-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/37/12886/abstract-text/9389261/pubmed\" id=\"9389261\" target=\"_blank\">",
"        9389261",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reynolds LM, Lau M, Brown R, et al, &ldquo;Bioavailability of Intramuscular Rocuronium in Infants and Children,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1997, 87(5):1096-105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/37/12886/abstract-text/9366462/pubmed\" id=\"9366462\" target=\"_blank\">",
"        9366462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Willets LS, &ldquo;Rocuronium for Tracheal Intubation,&rdquo;",
"      <i>",
"       Ped Pharmacotherapy",
"      </i>",
"      , 2000, 6(10):1-6.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12774 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12886=[""].join("\n");
var outline_f12_37_12886=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219069\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219070\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061877\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445026\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061870\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219051\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219037\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061880\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7282116\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061873\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061879\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219106\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219104\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061884\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061869\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061868\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300012\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219045\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219047\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219060\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061876\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061867\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061882\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061883\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=related_link\">",
"      Rocuronium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/52/27459?source=related_link\">",
"      Rocuronium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_37_12887="Livedoid vasculopathy";
var content_f12_37_12887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Livedoid vasculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Segmental hyalinizing vasculopathy. Hyalinized changes within the subintimal layer of blood vessel walls and vascular thrombosis in the superficial and deep dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hairston, BR, et al. Treatment of livedoid vasculopathy with low-molecular weight heparin. Arch Dermatol 2003 139:987. Copyright &copy;2003 American Medical Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12887=[""].join("\n");
var outline_f12_37_12887=null;
var title_f12_37_12888="Treatment of relapsed or refractory acute promyelocytic leukemia in adults";
var content_f12_37_12888=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsed or refractory acute promyelocytic leukemia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/37/12888/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/37/12888/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/37/12888/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/37/12888/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/37/12888/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/37/12888/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/37/12888/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute promyelocytic leukemia (APL) is a clinically and biologically distinct variant of acute myeloid leukemia (AML). It was classified as AML-M3 in the older French-American-British (FAB) classification system, and acute promyelocytic leukemia with t(15;17)(q24.1;q21.1);PML-RARA in the WHO classification system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39720?source=see_link\">",
"     \"Classification of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vast majority of patients with newly diagnosed APL can obtain a complete remission with induction therapy that incorporates all-trans retinoic acid (ATRA; tretinoin) followed by a molecular complete remission after consolidation therapy. It is extremely uncommon to have primary drug resistance in APL, and in general, the predominant cause of induction failure (5 to 10 percent) is death from hemorrhage or infection. Despite this, relapse occurs in 10 to 15 percent of patients with APL and in about 20 to 30 percent of those with high-risk APL as defined as those who present with a white blood cell count above 10,000 and a platelet count less than 40,000. Using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO) during consolidation of first complete remission may markedly reduce the relapse rate even in high-risk APL.",
"   </p>",
"   <p>",
"    The treatment of relapsed or refractory APL will be reviewed here. The clinical features, diagnosis, and prognosis of APL in adults are presented separately, as is the initial treatment of APL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistant or refractory APL is diagnosed in those patients who either fail to attain a cytologic complete remission with induction chemotherapy or fail to attain a complete molecular remission following several cycles of consolidation chemotherapy. Response criteria are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We consider patients to have relapsed disease if, after attainment of complete molecular remission, subsequent analyses confirm the loss of such molecular remission or identify extramedullary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several treatment regimens have been utilized to treat refractory and relapsed disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/1\">",
"     1",
"    </a>",
"    ]. These include ATRA, anthracyclines, high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , autologous or allogeneic hematopoietic cell transplantation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     gemtuzumab ozogamicin",
"    </a>",
"    . The choice of therapy and the likelihood of cure depend in part upon whether ATRA was given together with an anthracycline drug during the first remission and whether the relapse occurred while the patient was still receiving therapy.",
"   </p>",
"   <p>",
"    Long-term follow-up of 380 patients initially treated with ATRA therapy demonstrated that most relapses occur during the first three years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/2\">",
"     2",
"    </a>",
"    ]. Late relapses are uncommon, accounting for less than 5 percent of relapses, and are likely to have durable responses with second line therapy.",
"   </p>",
"   <p>",
"    The molecular pathways involved in relapsed or refractory APL are poorly understood, but likely differ depending upon the type of initial treatment and the timing of relapse in relation to treatment. As an example, in an analysis of 45 patients with relapsed APL following initial treatment with ATRA plus chemotherapy, 18 cases (40 percent) demonstrated point mutations in the ligand binding domain of PML-RARalpha [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with PML-RARalpha point mutations had progressive disease while receiving ATRA therapy (11 cases) or progressed following the completion of ATRA therapy (seven cases), suggesting selection pressure due to both ATRA therapy and ATRA-independent mechanisms of progression. In contrast, patients within the same study who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    as part of their initial therapy had a lower rate of progression, perhaps due to elimination of clones containing PML-RARalpha point mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Arsenic trioxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     Arsenic trioxide",
"    </a>",
"    (ATO) is the treatment of choice for most patients with relapsed APL. Complete remission (CR) can be obtained in 85 to 88 percent of patients. It is unclear whether adding ATRA to ATO is better than ATO alone. ATO is able to penetrate the blood-brain barrier and so can be used in patients with CNS involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/4\">",
"     4",
"    </a>",
"    ]. This therapy is then followed by consolidation treatment, which is selected based upon the depth of response and patient characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a second remission is obtained and reverse transcription polymerase chain reaction (RT-PCR) testing is negative for the",
"      <span class=\"nowrap\">",
"       PML/RAR-alpha",
"      </span>",
"      transcript, consolidation with either autologous hematopoietic cell transplantation (HCT), allogeneic HCT, or further ATO is given. Autologous HCT is usually preferred because of its association with less toxicity and morbidity. However, if the patient is young (eg, less than 30 years of age) and without comorbid conditions, allogeneic HCT is an equally effective choice with a potential, yet unproven improvement in disease control.",
"     </li>",
"     <li>",
"      If PCR negativity is not obtained, allogeneic HCT becomes the favored treatment, but alternative treatments such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"       gemtuzumab ozogamicin",
"      </a>",
"      may be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of studies have shown a high response rate following therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    (ATO) in patients with relapsed APL [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/5-10\">",
"     5-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case series included 26 patients with relapsed APL who received induction therapy with ATO (0.06 to 0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. CR was achieved in 88 percent at a median time of 47 days. A rising white blood cell count (WBC)",
"      <span class=\"nowrap\">",
"       &gt;10,000/microL",
"      </span>",
"      was noted during ATO treatment in 15 patients, with the WBC exceeding",
"      <span class=\"nowrap\">",
"       100,000/microL",
"      </span>",
"      in three. Eight patients (31 percent) developed \"differentiation syndrome\" at a mean time of 17 days (range 7 to 24 days), and required treatment with corticosteroids. This syndrome was only noted during induction therapy with ATO; neither leukocytosis nor the differentiation syndrome was seen during any postremission courses. Three patients remained positive for the",
"      <span class=\"nowrap\">",
"       PML/RAR-alpha",
"      </span>",
"      transcript and relapsed early [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a larger series, 47 patients with relapsed APL (43 in first relapse and 2 each in 2nd and 3rd relapse) received ATO with or without other agents; 31 with ATO alone, 11 with ATO and moderate chemotherapy, and 5 with ATO and ATRA [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/5\">",
"       5",
"      </a>",
"      ]. CR was obtained in 85 percent, with median disease-free and overall survival rates of 17 and 25 months, respectively. More than two-thirds of the patients treated with ATO alone or chemotherapy alone after attaining CR subsequently relapsed, as compared with only 2 of 11 patients treated with ATO and chemotherapy after attaining CR. Most of the side effects (liver, GI, skin, cardiac) were modest and responded to symptomatic treatment.",
"     </li>",
"     <li>",
"      In a multicenter trial of 40 patients with APL in first or second relapse, CR following treatment with ATO was attained in 85 percent, 91 percent of whom had negative post-treatment cytogenetic tests for t(15;17) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/10\">",
"       10",
"      </a>",
"      ]. Overall and relapse-free survival rates at 18 months were 66 and 56 percent, respectively. Ten patients developed the \"APL differentiation syndrome\" and were effectively treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      . Prolongation of the QT interval was seen in 63 percent; one patient had an asymptomatic 7-beat run of torsade. There were two deaths during induction, unrelated to drug treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with resistant or relapsed disease, we suggest treatment with one or two cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV for 25 consecutive doses (or five doses per week for five weeks), followed by autologous HCT in patients who achieve a CR and are RT-PCR negative. Allogeneic HCT can be considered if a suitable donor is available, but for APL, allogeneic HCT is not clearly better than autologous HCT. For patients who do not achieve RT-PCR negativity, allogeneic HCT is the preferred treatment in eligible patients with an available donor.",
"   </p>",
"   <p>",
"    Studies of combination therapy with other agents are ongoing and have mixed preliminary results. As an example, a small randomized study of 20 patients with APL relapsed after initial treatment with ATRA and anthracycline-based chemotherapy, found no benefit with the addition of ATRA to ATO [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/11\">",
"     11",
"    </a>",
"    ]. Another small pilot study suggested additional benefit when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     gemtuzumab ozogamicin",
"    </a>",
"    was added as consolidation after ATO [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious adverse events attributed to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    include fluid retention, the \"differentiation syndrome\" (similar to that seen with retinoic acid), peripheral sensory neuropathy, electrocardiographic abnormalities (eg, QT interval prolongation and complete atrioventricular block) and sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=see_link\">",
"     \"Differentiation (retinoic acid) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an initial report, all eight patients treated with this agent developed QT prolongation and four developed nonsustained ventricular tachycardia requiring treatment with antiarrhythmic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/16\">",
"     16",
"    </a>",
"    ]. A lower risk was noted in a much larger series of 99 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/15\">",
"     15",
"    </a>",
"    ]. Reversible prolongation of the QT interval to &gt;500 msec occurred in 38 patients; the risk was increased in patients with hypokalemia, with one hypokalemic patient developing torsade de pointes. Hyperglycemia has also been noted.",
"   </p>",
"   <p>",
"    Labeling instructions for this agent recommend that, during therapy, serum potassium concentrations should be kept &gt;4.0",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and magnesium concentrations &gt;1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/19\">",
"     19",
"    </a>",
"    ]. ATO should be held if the absolute QT interval exceeds 500 msec or if the patient develops syncope or an irregular heartbeat. ATO can be reinstated if these symptoms resolve and the absolute QT interval decreases to 460 msec or below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     \"Arsenic trioxide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately half of patients will develop a leukocytosis that peaks at approximately day 20 and usually resolves at a median of 10.5 days after the peak, despite continuation of ATO therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     Arsenic trioxide",
"    </a>",
"    is eliminated mainly by renal excretion. Accordingly, uremic patients are considered unsuitable for treatment with this agent. However, one patient with relapsed APL and chronic renal failure, who was receiving continuous ambulatory peritoneal dialysis, has been successfully treated with arsenic trioxide, although at a reduced dose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     Gemtuzumab ozogamicin",
"    </a>",
"    is an anti-CD33 monoclonal antibody conjugated with the cytotoxic agent calicheamicin. The CD33 antigen is strongly expressed on APL cells, suggesting its use in APL. Clinical trials are now evaluating its benefit in combination with ATRA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ATO for newly diagnosed patients with APL. The US Food and Drug Administration has required that gemtuzumab be removed from the market in the United States, but it continues to undergo evaluation in clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Immunophenotype'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=see_link&amp;anchor=H21585075#H21585075\">",
"     \"Treatment of relapsed or refractory acute myeloid leukemia\", section on 'Gemtuzumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Case reports and small case series have reported on the successful use of single agent gemtuzumab in the treatment of patients with relapsed APL [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. As an example, in one study, 14 of 16 patients with APL in molecular relapse responded to treatment with gemtuzumab (6",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    by IV infusion over two hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/26\">",
"     26",
"    </a>",
"    ]. Of the 13 patients receiving three doses of this agent, all attained a new molecular remission. In addition, gemtuzumab has demonstrated activity when administered in combination with ATRA and ATO in patients with relapsed APL [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chemotherapy and ATRA for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have received ATRA plus anthracycline treatment during first remission are less likely to be cured by reinstitution of the same treatment at the time of relapse, although a second remission can often be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/1\">",
"     1",
"    </a>",
"    ]. The best outcomes in these patients are likely to follow hematopoietic cell transplantation, either at the time of relapse or, preferably, soon after a second CR has been obtained.",
"   </p>",
"   <p>",
"    In one study, 35 patients treated after first relapse or primary induction failure received one course of chemotherapy combining an anthracycline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    with or without ATRA [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/27\">",
"     27",
"    </a>",
"    ]. Complete remission was achieved in 29 of 38 patients. Four of five patients who had initially received ATRA achieved a second CR when retreated with ATRA. The only factor predictive of poor prognosis for overall survival was the absence of ATRA therapy at the time of relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Autologous transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of autologous hematopoietic cell transplantation (HCT) performed in second remission suggest that there is prognostic relevance to pretransplant minimal disease assessment by RT-PCR.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, all seven PCR-positive patients relapsed at a median time of five months following HCT and nine months from the time of second CR. Of the eight PCR-negative patients, one relapsed at 10 months following HCT, one died of a second leukemia, and six remained in hematologic and molecular remission at a median time of 28 months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second, larger study evaluated results in 50 patients with APL who received autologous HCT while in second complete remission [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/1\">",
"       1",
"      </a>",
"      ]. Treatment-related mortality was 6 percent. For patients in molecular remission at the time of stem cell collection, the seven-year relapse-free survival was 87 percent.",
"     </li>",
"     <li>",
"      A third study of autologous HCT in 51 patients with de novo AML in second complete remission included 12 patients (24 percent) with APL [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/29\">",
"       29",
"      </a>",
"      ]. Treatment consisted of consolidation chemotherapy with high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      to mobilize stem cells for collection, followed by a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      plus etoposide preparative regimen and autologous HCT. The subset of patients with APL demonstrated five-year disease-free and overall survival rates of 67 percent each with this treatment approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies support the use of autologous HCT in patients who achieve a second molecular complete remission and discourage its use in those who do not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Allogeneic transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic HCT is capable of producing long-term remissions in patients with APL who have achieved a second CR. In an EBMT survey of 137 such patients, 5-year leukemia-free survival was 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, high rates of non-relapse mortality have been a problem, the rates of which vary depending upon risk factors such as age and comorbid conditions. In one series, treatment-related mortality was 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/31\">",
"     31",
"    </a>",
"    ], while non-relapse mortality was 32 percent in another [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/32\">",
"     32",
"    </a>",
"    ]. In contrast to the results with autologous HCT, molecular remission at the time of allogeneic HCT may be less important. In two studies, only 3 of 12 PCR-positive patients relapsed following allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/1,32\">",
"     1,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Future therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other investigational approaches have been evaluated for treatment of ATRA-resistant APL. Three such approaches include use of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    , novel retinoids, and monoclonal antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Novel retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novel retinoids under study in patients with relapsed APL include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A liposomal formulation of ATRA available in a parenteral form for patients with severe mucositis or other gastrointestinal tract compromise [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tamibarotene (Am-80) is a more potent orally available synthetic retinoid undergoing investigation in a multicenter phase II trial [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-CD 33 antibodies (HuM195 and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     gemtuzumab ozogamicin",
"    </a>",
"    ) have been useful in the eradication of minimal residual disease following treatment with ATRA-containing regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF EXTRAMEDULLARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 10 percent of patients with relapsed APL will demonstrate involvement of the central nervous system (CNS) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, 3 to 5 percent of patients will have extramedullary disease at other sites, in the form of myeloid sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/20\">",
"     20",
"    </a>",
"    ]. There are limited data on the treatment of these patients and most experts extrapolate from their experience treating patients with acute lymphoblastic leukemia (ALL) or other forms of AML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Central nervous system involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with relapsed APL should have a lumbar puncture to assess involvement of the CSF. Patients with CNS involvement at the time of relapse require both therapy directed at the CNS and systemic therapy as given to all patients with relapse. CNS directed therapy is largely extrapolated from experience with patients with ALL. This is described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=see_link\">",
"     \"Involvement of the central nervous system with acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Myeloid sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloid sarcoma (also called granulocytic sarcoma or chloroma) is defined by prominent extramedullary sites of leukemia, most commonly related to either cutaneous or nodal infiltration by leukemic cells, but any organ can be involved. Although some experts advocate treatment of localized myeloid sarcoma in relapsed APL with local radiation to the extramedullary disease site, most often, systemic therapy for relapsed disease is required as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MONITORING DURING THERAPY AND SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of cytopenias, infections, tumor lysis, menorrhagia, and other complications common to all patients with AML are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H14#H14\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Supportive care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37285?source=see_link\">",
"     \"Heavy or irregular uterine bleeding during chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link\">",
"     \"Overview of the complications of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of coagulopathy, differentiation syndrome, and leukocytosis are also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Monitoring during therapy and supportive care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=see_link\">",
"     \"Differentiation (retinoic acid) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An electrocardiogram (ECG) should be obtained prior to initiating ATO therapy to assess for congenital QT prolongation or the pharmacologic effects of concomitant medications. ECG monitoring should then be repeated after several days on treatment, at the initiation of subsequent courses of ATO, and after beginning treatment with other medications known to prolong the QT interval. Alternatively, some centers assess weekly ECGs to monitor the QT interval at other institutions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     THERAPY RELATED MYELOID NEOPLASMS AFTER APL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports of myelodysplastic syndrome (MDS)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute myeloid leukemia (AML) following successful treatment of APL have appeared in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. In a single institution report of 88 consecutively diagnosed and treated patients with APL, of whom 77 obtained hematologic and molecular remission, MDS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AML developed in five patients 24 to 48 months after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12888/abstract/39\">",
"     39",
"    </a>",
"    ]. All five had negative",
"    <span class=\"nowrap\">",
"     PML/RARa",
"    </span>",
"    status when this complication occurred; new chromosomal changes included monosomy 7 and del(5q-) in one patient each, consistent with therapy-related",
"    <span class=\"nowrap\">",
"     MDS/AML.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H13#H13\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vast majority of patients with newly diagnosed acute promyelocytic leukemia (APL) can obtain a complete remission (CR) with induction therapy that incorporates all-trans retinoic acid (ATRA; tretinoin) together with chemotherapy followed by a molecular complete remission after consolidation therapy. The cure rate is high when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"       arsenic trioxide",
"      </a>",
"      (ATO) is included in the consolidation sequence. Despite this, relapse occurs in 5 to 10 percent of patients with APL and in about 20 to 30 percent of those with high-risk APL as defined as those who present with a white blood cell count above",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"      and a platelet count less than",
"      <span class=\"nowrap\">",
"       40,000/microL.",
"      </span>",
"      Consolidation therapy with ATO has proven remarkably effective at reducing the relapse rate even in high-risk APL.",
"     </li>",
"     <li>",
"      We consider patients to have resistant disease if they have not achieved complete molecular remission following two to three cycles of consolidation chemotherapy. We consider patients to have relapsed disease if, after attainment of complete molecular remission, subsequent analyses confirm the loss of such molecular remission. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with resistant or relapsed disease, we suggest treatment with two courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"       arsenic trioxide",
"      </a>",
"      0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV for 25 consecutive doses (or five doses per week for five weeks), followed by autologous hematopoietic cell transplantation (HCT) in patients who achieve a CR and are RT-PCR negative (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Allogeneic HCT can be considered if a suitable donor is available, but in the setting of APL, allogeneic HCT is not clearly better than autologous HCT. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Arsenic trioxide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      APL cells have high expression of CD33. Where available, the anti-CD33 monoclonal antibody conjugate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"       gemtuzumab ozogamicin",
"      </a>",
"      can effectively control disease in patients with APL who have had a molecular relapse. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Gemtuzumab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/1\">",
"      de Botton S, Fawaz A, Chevret S, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005; 23:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/2\">",
"      Douer D, Zicki L, Schiffer CA, et al. Late relapses following all-trans retinoic acid for acute promyelocytic leukemia are uncommon, respond well to salvage therapy and occur independently of prognostic factors at diagnosis: Long-term follow-up of North American Intergroup Study 10129 (abstract 83). Blood 2011; 118:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/3\">",
"      Gallagher RE, Moser BK, Racevskis J, et al. Treatment-influenced associations of PML-RAR&alpha; mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood 2012; 120:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/4\">",
"      Au WY, Tam S, Fong BM, Kwong YL. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 2008; 112:3587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/5\">",
"      Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/6\">",
"      Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89:3354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/7\">",
"      Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/8\">",
"      Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/9\">",
"      Kwong YL, Au WY, Chim CS, et al. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol 2001; 66:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/10\">",
"      Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19:3852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/11\">",
"      Raffoux E, Rousselot P, Poupon J, et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/12\">",
"      Aribi A, Kantarjian HM, Estey EH, et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 2007; 109:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/13\">",
"      Unnikrishnan D, Dutcher JP, Garl S, et al. Cardiac monitoring of patients receiving arsenic trioxide therapy. Br J Haematol 2004; 124:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/14\">",
"      Chiang CE, Luk HN, Wang TM, Ding PY. Prolongation of cardiac repolarization by arsenic trioxide. Blood 2002; 100:2249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/15\">",
"      Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003; 21:3609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/16\">",
"      Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000; 133:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/17\">",
"      Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/18\">",
"      Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/19\">",
"      Singer JW. Cardiac toxicity of arsenic trioxide. Blood 2001; 98:1633; author reply 1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/20\">",
"      Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/21\">",
"      Au WY, Cheung GT, Yuen TW, et al. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide. Arch Intern Med 2005; 165:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/22\">",
"      Petti MC, Pinazzi MB, Diverio D, et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol 2001; 115:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/23\">",
"      Lo Coco F, Ammatuna E, Noguera N. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clin Adv Hematol Oncol 2006; 4:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/24\">",
"      Breccia M, Cimino G, Diverio D, et al. Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica 2007; 92:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/25\">",
"      Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin (\"mylotarg\") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99:4222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/26\">",
"      Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/27\">",
"      Thomas X, Anglaret B, Thiebaut A, et al. Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy. Ann Hematol 1997; 75:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/28\">",
"      Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997; 90:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/29\">",
"      Linker CA, Owzar K, Powell B, et al. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant 2009; 44:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/30\">",
"      Sanz MA, Labopin M, Gorin NC, et al. Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007; 39:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/31\">",
"      Sainty D, Liso V, Cant&ugrave;-Rajnoldi A, et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood 2000; 96:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/32\">",
"      Lo-Coco F, Romano A, Mengarelli A, et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 2003; 17:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/33\">",
"      Douer D, Estey E, Santillana S, et al. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood 2001; 97:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/34\">",
"      Takeuchi M, Yano T, Omoto E, et al. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Leuk Lymphoma 1998; 31:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/35\">",
"      Jurcic JG, DeBlasio T, Dumont L, et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000; 6:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/36\">",
"      Zompi S, Legrand O, Bouscary D, et al. Therapy-related acute myeloid leukaemia after successful therapy for acute promyelocytic leukaemia with t(15;17): a report of two cases and a review of the literature. Br J Haematol 2000; 110:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/37\">",
"      Pecci A, Invernizzi R. A therapy-related myelodysplastic syndrome with unusual features in a patient treated for acute promyelocytic leukemia. Haematologica 2001; 86:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/38\">",
"      Au WY, Lam CC, Ma ES, et al. Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features. Hum Pathol 2001; 32:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12888/abstract/39\">",
"      Latagliata R, Petti MC, Fenu S, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002; 99:822.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4505 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-DE283444F4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12888=[""].join("\n");
var outline_f12_37_12888=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Arsenic trioxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chemotherapy and ATRA for relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Autologous transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Allogeneic transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Future therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Novel retinoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT OF EXTRAMEDULLARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Central nervous system involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Myeloid sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MONITORING DURING THERAPY AND SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      THERAPY RELATED MYELOID NEOPLASMS AFTER APL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=related_link\">",
"      Arsenic trioxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39720?source=related_link\">",
"      Classification of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37384?source=related_link\">",
"      Differentiation (retinoic acid) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37285?source=related_link\">",
"      Heavy or irregular uterine bleeding during chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25607?source=related_link\">",
"      Involvement of the central nervous system with acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=related_link\">",
"      Treatment of relapsed or refractory acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_37_12889="Histology nevoid melanoma 2";
var content_f12_37_12889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nevoid melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 520px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Medium power light photomicrograph of a nevoid melanoma, demonstrating striking hypercellularity and hyperchromasia in the dermal component. Panel B: High power light photomicrograph view of the same lesion. The neoplastic cells are hyperchromatic and pleomorphic. Note a readily observed mitosis in the center of the field (red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12889=[""].join("\n");
var outline_f12_37_12889=null;
var title_f12_37_12890="Pain assessment and management in the last weeks of life";
var content_f12_37_12890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pain assessment and management in the last weeks of life",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/37/12890/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/37/12890/contributors\">",
"     Kathleen Broglio, MN, ANP-BC, ACHPN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/37/12890/contributors\">",
"     Russell K Portenoy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/37/12890/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/37/12890/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/37/12890/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/37/12890/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/37/12890/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most people die after a period of deterioration caused by one or more chronic progressive illnesses. The suffering that characterizes the period before death can be related, at least in part, to the experience of unrelieved symptoms.",
"   </p>",
"   <p>",
"    Pain is among the most prevalent of these symptoms. When pain is unrelieved, it can be a source of great distress. This distress not only can affect the patient but also may extend to family caregivers, who may experience guilt, anger directed at medical personnel, or regret that persists long into the future. The care of patients with unrelieved pain also may adversely affect professional caregivers, potentially increasing the risk of burnout.",
"   </p>",
"   <p>",
"    The proper management of pain at the end of life is imperative and the necessary analgesic interventions are well within the purview of primary care providers. All clinicians who care for the chronically ill should acquire basic skills in pain management.",
"   </p>",
"   <p>",
"    The assessment and management of pain in the last weeks of life are discussed here. The ethical issues surrounding pain control at the end of life, management of symptoms, including pain, in the last hours to days of life, and control of other symptoms in patients in the last days to weeks of life are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19477?source=see_link\">",
"     \"Ethical considerations in effective pain management at the end of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./palliative-sedation?source=see_link\">",
"     \"Palliative sedation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE OF PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is widely prevalent in the last weeks of life regardless of the setting in which patients are being managed. As an example, one estimate suggests that at least one-fifth of the million patients who die in hospitals each year experienced pain during the final admission [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, a survey of hospice patients in nursing homes found that about 50 percent had daily pain, which was moderate or worse in about 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/2\">",
"     2",
"    </a>",
"    ]. Similarly, in a survey of Americans with terminal illness living at home, 50 percent had moderate to severe pain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain is a common feature in the last weeks of life with many illnesses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer pain has been most extensively studied. Moderate to severe chronic pain is experienced by at least 70 percent of patients with advanced cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/4\">",
"       4",
"      </a>",
"      ]. A unique observational cohort study of all cancer decedents in Ontario Canada between 2007 and 2009 provides data on the prevalence and trajectory of moderate to severe symptoms, including pain, in the last six months of life for patients with terminal cancer (",
"      <a class=\"graphic graphic_figure graphicRef59669 \" href=\"UTD.htm?34/45/35537\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, pain at the end of life was recorded in more than 93 percent of patients dying from",
"      <span class=\"nowrap\">",
"       HIV/AIDS,",
"      </span>",
"      although pain prevalence has declined with the advent of retroviral therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other studies have suggested that as many as 75 percent of patients with heart failure experience pain during the last six months of life [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/7\">",
"       7",
"      </a>",
"      ], which often is related to comorbidities such as osteoarthritis or diabetes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=see_link\">",
"       \"Assessment of cancer pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persistent pain is prevalent in diverse populations with neurologic diseases such as multiple sclerosis and cerebrovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. These pain syndromes are poorly understood and treatment may be challenging.",
"     </li>",
"     <li>",
"      Pain appears to be highly prevalent in people with dementia, the most common neurologic disorder associated with end of life care, and in this context poses unique challenges due to assessment difficulties [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/10\">",
"       10",
"      </a>",
"      ]. Osteoarthritis, contractures, pressure ulcers, and other lesions are common in those with advanced dementia and can be sources of significant pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the setting in which patients receive care in the last weeks of life and independent of the specific illnesses being treated, studies using validated scales suggest that pain often is highly distressing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Among those with far advanced disease, pain and other symptoms usually are associated with progressive decline in functioning and other complications such as weight loss. Furthermore, management of pain with analgesics may be an ongoing process as disease progresses, requiring changes in medications or escalation of dose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Undertreatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a strong consensus that pain at the end of life should be treated aggressively with opioid-based pharmacotherapy and other measures as needed. Nonetheless, surveys of patient populations to determine the adequacy of pain management have found that pain associated with advanced illness is widely undertreated.",
"   </p>",
"   <p>",
"    Undertreatment of cancer pain has been estimated to be as high as 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/14\">",
"     14",
"    </a>",
"    ]. Similarly, in a large survey of hospitalized patients with advanced illness, family members reported moderate to severe pain at least one half of the time in 50 percent of conscious patients who died in the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/15\">",
"     15",
"    </a>",
"    ]. Knowledge of pain management among clinicians has been shown to be inadequate and institution-wide interventions designed to improve knowledge and practice have yet to demonstrate effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of undertreatment presumably varies with characteristics of the patient, clinician, and setting. Investigation of these factors has been limited. Studies suggest that minority status, female sex, older age, and a history of substance abuse each increase the risk of undertreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]. Among institutionalized elderly patients with cancer, undertreatment has been linked to age greater than 85 years, minority race, impaired cognition, and the requirement for multiple medications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barriers to effective pain management are multifactorial and include problems with professional competency, patient-related factors such as stoicism and fear of treatments, and impediments inherent in the health care delivery system. As an example, studies in cancer patients suggest that undertreatment is related to the combined effects of clinician's lack of knowledge, attitudes that diminish the perceived importance of pain management, and fear of hastening death; patient underreporting and therapeutic nonadherence; patient or family belief in the inevitability of pain or fear of addiction and tolerance; and system-wide impediments to optimal analgesic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/19-23\">",
"     19-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT AS A COMPONENT OF PALLIATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative care is an interdisciplinary approach that focuses on the comprehensive management of the physical, psychological, social, and spiritual needs of patients with serious or life-threatening diseases and their families [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/24\">",
"     24",
"    </a>",
"    ]. Palliative care is a growing practice specialty for clinicians, nurses, social workers, chaplains, and others; in 2006, Hospice and Palliative Medicine became a recognized subspecialty for clinicians in the United States. Palliative medicine specialists are experts on end-of-life concerns, and, while palliative care is useful even at the time of diagnosis of a serious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    life-threatening illness, the end of life is often when the need for specialist-level care is greatest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=see_link\">",
"     \"Overview of comprehensive patient assessment in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overriding goal of palliative care is to reduce suffering and maintain an acceptable quality of life throughout the course of a progressive illness, including the periods of advanced illness and active dying.",
"   </p>",
"   <p>",
"    Specific goals of palliative care include ensuring that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The values and decisions of the patient and family are respected",
"     </li>",
"     <li>",
"      Open and accurate communication is supported",
"     </li>",
"     <li>",
"      Comfort needs are continually addressed",
"     </li>",
"     <li>",
"      Psychosocial and spiritual distress is managed",
"     </li>",
"     <li>",
"      Care is coordinated across treatment settings",
"     </li>",
"     <li>",
"      Practical support is available in the home",
"     </li>",
"     <li>",
"      Expertise is available to manage the challenging period of active dying.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the many interventions subsumed by palliative care typically intensify during the periods of advanced illness and active dying, the effort to address quality-of-life concerns should ideally be integrated with disease-modifying and other therapies throughout the course of an illness. Accordingly, \"generalist-level\" palliative care should be considered part of best practice in the care of every appropriate clinical population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link&amp;anchor=H549034653#H549034653\">",
"     \"Palliative care: Benefits, services, and models of care\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain management in populations with serious and advanced illness should be understood within a broader palliative care model. The concept of \"total pain\" recognizes that pain at the end of life encompasses more than the \"physical\" pain associated with the physical ravages of disease, and can include emotional, social, and spiritual aspects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/25\">",
"     25",
"    </a>",
"    ]. Comprehensive pain assessment must include all these factors in an effort to understand the contribution of pain to suffering. As described a document known as the Consensus Project for Best Practices in Palliative Care, pain and symptom control is a key domain of palliative care but must be combined with other strategies in a broader approach to the patient with serious or life-threatening illness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Goal setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal palliative care continually strives to clarify the goals of treatment interventions and determine whether they are consistent with the values and decisions of the patients, and the reality of the disease process.",
"   </p>",
"   <p>",
"    When considering analgesic therapy for pain, goals that health care professionals often take for granted, such as the desire for alertness or the ability to ambulate, may change dramatically in the context of advanced illness. To clarify the best approach for pain management in an individual patient, the clinician must explore the willingness of the patient to tolerate side effects or reduced functioning in order to achieve relief, the openness of the patient to procedures such as nerve blocks or neuraxial infusion, and the ability of the family to understand and support the patient in decision making.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Care setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The setting in which patients receive end-of-life care strongly influences the extent to which pain management and the more comprehensive goals of palliative care can be pursued. Surveys indicate that most people would prefer to die at home, but the reality is that fewer than one-quarter of patients in the United States actually do. About 50 percent die in the hospital and 25 percent die in nursing homes or other long-term care facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/27\">",
"     27",
"    </a>",
"    ]. Although utilization of home hospice programs has increased, only 42 percent of Americans who die access hospice services and the median length of stay is only 20 days [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians who are managing pain at the end of life must be aware of the resources and constraints imposed by the treatment setting, including the skills of front-line health-care providers, availability of medications, and other issues. Access to specialist palliative care is increasing, primarily through hospice programs and institution-based palliative care consultation teams, which ultimately may be an important resource for pain management in most settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PAIN ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of pain at the end of life should be guided by a comprehensive assessment of both pain and other symptoms. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link\">",
"     \"Approach to symptom assessment in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pain assessment begins with a detailed characterization of the pain. Specific questions should be directed to pain location; onset, duration, course and daily fluctuation; severity; quality; factors that relieve or provoke the pain; and associated symptoms. The impact of the pain on varied functional domains, including physical activity, mood, interactions in the family and others, should be clarified. Information about the prior evaluation of the pain and the outcomes of prior and existing analgesic therapies should be noted.",
"   </p>",
"   <p>",
"    A key goal in the pain assessment is to understand the etiology of the pain and the pathophysiologic processes that are sustaining it. In many cases, a specific syndrome can be identified. Understanding the etiology of the pain may facilitate disease-modifying therapy, which can have analgesic consequences (for example, radiation therapy for bone metastases). In addition, inferences about pathophysiology may guide analgesic drug selection and other interventions. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pharmacotherapy'",
"    </a>",
"    below.) Diagnostic interventions to determine the source of the pain may present more of a burden than a benefit, however, in patients with advanced disease who are not candidates for surgical or radiation therapy.",
"   </p>",
"   <p>",
"    The ability to assess pain characteristics, including severity, may become compromised as cognitive functioning declines, and it may be necessary to supplement verbal reports with behavioral measures of pain severity. These include vocalization, breathing patterns, facial patterns, and consolability. If desired, a validated tool based on these behaviors can be used to obtain greater precision. These tools, such as the Pain Assessment in Advanced Dementia (PAINAID), Behavioral Pain Scale (BPS), and the Critical Care Pain Observation Tool (CPOT) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], are generally used in research settings.",
"   </p>",
"   <p>",
"    Although it is appropriate to query a family caregiver to obtain information about potential pain and other sources of distress when cognitive impairment precludes direct assessment, clinicians must exercise caution when relying on proxy reports. As an example, in a large cohort of hospitalized patients with advanced illness, surrogates correctly identified the existence of pain 73 percent of the time, but accurately estimated its severity only 53 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/32\">",
"     32",
"    </a>",
"    ]. A proxy report should be viewed as one source of information that can be used to inform treatment in the cognitively impaired patient.",
"   </p>",
"   <p>",
"    Given the risk of undertreatment, clinicians should assess pain frequently and maintain a low threshold for the conclusion that pain exists. Noting the physical condition of the patient, the clinician should ask \"would I be in pain?\" If the answer is \"yes,\" it is best to assume that pain exists and that intervention is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy is the mainstay of treatment for pain at the end of life. There are three broad categories of analgesic medications: opioids, nonopioid analgesics (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and the nonsteroidal anti-inflammatory drugs), and the so-called adjuvant analgesics, which comprise numerous agents in diverse classes. Most adjuvant analgesics are commercially available for indications other than pain but are analgesic in specific circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OPIOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid analgesics are the mainstay for the treatment of moderate to severe pain in patients with advanced illness. When optimally administered according to accepted guidelines, these drugs provide adequate relief to more than three-quarters of patients with cancer pain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with advanced illness, chronic pain is typically best treated using a pure mu agonist drug available as a single entity (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"     table 1",
"    </a>",
"    ). In the US, this category includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/22/29029?source=see_link\">",
"     levorphanol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    . There is no uniformly preferred agent and there is substantial individual variation in the response to these drugs. The selection of one drug over another is typically based on clinical judgment and factors such as formulary access, cost, or availability of a parenteral formulation.",
"   </p>",
"   <p>",
"    Clinicians should be prepared to switch from one drug to another should a therapeutic trial demonstrate that the balance between analgesia and side effects is not favorable. Opioid switching of this type is known as \"opioid rotation\" and is a widely accepted approach to the management of a patient who is not responding well to an opioid regimen. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Opioid rotation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Morphine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    has the longest history in the treatment of pain and is usually considered to be a standard for comparison across opioid drugs.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    is primarily metabolized in the liver and its metabolites are excreted renally. Two active metabolites have been extensively studied, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. M6G is an opioid and appears to contribute to the analgesia and other opioid effects produced by the administration of morphine. In contrast, M3G is not an opioid, but binds to other receptors and may be associated with toxic effects, particularly when the concentration of metabolites is relatively high.",
"   </p>",
"   <p>",
"    Metabolite concentration can be high idiosyncratically, presumably as a result of unknown genetic factors, or as a result of renal disease that reduces excretion. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    should be administered cautiously in the setting of renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/37\">",
"     37",
"    </a>",
"    ] or if fluctuation in renal function can be anticipated as a result of treatments with nephrotoxic side effects or disease progression.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    is available in many formulations, including once-daily and twice-daily modified-release oral formulations, oral solutions or elixirs, suppositories, and injectable solutions. (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"     table 1",
"    </a>",
"    ) The availability of a concentrated oral solution and suppositories may provide a means to treat some patients who are unable to tolerate most oral medications but have no access to, or desire for, subcutaneous or intravenous infusion. Although morphine has been widely used sublingually in the hospice setting, it is poorly absorbed by this route and is therefore not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other short half-life opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three other opioids available in the United States (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    ) have short half-lives similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    and are available in multiple formulations, including an oral formulation and modified release formulations that permit a dosing interval of 12 or 24 hours (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"UTD.htm?11/31/11760\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Specific indications that can lead to a preference for one or another of these agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parenteral administration &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       Hydromorphone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/8/32903?source=see_link\">",
"       oxymorphone",
"      </a>",
"      have parenteral formulations and may be particularly useful for parenteral administration when oral intake becomes compromised at the end of life. Hydromorphone is relatively soluble in water and can easily be concentrated; a commercially available formulation at 10 mg per mL allows relatively high dose treatment during subcutaneous or intravenous administration.",
"     </li>",
"     <li>",
"      Renal insufficiency &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       Hydromorphone",
"      </a>",
"      may be preferred for patients with renal insufficiency because its active metabolites, which are glucuronidated molecules similar to those produced by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , are present in low concentration and may be less likely to cause unanticipated effects.",
"     </li>",
"     <li>",
"      Itching and urticaria &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/8/32903?source=see_link\">",
"       Oxymorphone",
"      </a>",
"      might be preferred in those predisposed to develop itch or urticaria from opioids, because it has a low propensity to release histamine. This characteristic is shared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fentanyl",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    is a synthetic opioid available in transdermal, oral transmucosal, and injectable formulations.",
"   </p>",
"   <p>",
"    A trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    may be useful when rotating from one opioid to another. Fentanyl may offer particular advantages for patients in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with difficulty swallowing, where the transdermal and transmucosal formulations may be a particular advantage.",
"     </li>",
"     <li>",
"      Those who have itching or urticaria, in response to opioids, since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      has a relatively low propensity to cause histamine release.",
"     </li>",
"     <li>",
"      Those with renal insufficiency, since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      has no active metabolites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The transdermal formulation, which has a duration of effect of two to three days, may not be as useful if rapid titration of dose is needed. Furthermore, heat changes the dose delivery rate from the patch. Thus, patients with advanced illness who have recurrent fevers may be at increased risk of unexpected toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Levorphanol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/22/29029?source=see_link\">",
"     Levorphanol",
"    </a>",
"    has a relatively long half-life (12 to 16 hours) and interacts with both the mu and delta opioid receptors. Experience in the use of this drug is relatively limited in the United States, but it does present another option for the treatment of those with advanced illness, particularly when other drugs have not been well tolerated or are unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Methadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    for pain has been increasing steadily, driven by its low cost and clinical observations suggesting a potency and efficacy that can be unexpectedly high [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     Methadone",
"    </a>",
"    has several features among the pure mu agonist subclass of opioids that contribute to its effectiveness in some settings but make its use a challenge:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States and most other countries,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      is marketed as a racemic mixture of d- and l-isomers. The d-isomer is not an opioid, but rather is a relatively potent N-methyl-D-aspartate (NMDA) inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/39\">",
"       39",
"      </a>",
"      ]. NMDA antagonism produces analgesia and reverses opioid tolerance. These effects of the d-isomer may explain the unanticipated potency (ie, a dose produces a larger effect than would otherwise be anticipated) or efficacy (more analgesia occurs than that obtained with another opioid) that may be observed when another opioid has not yielded a favorable outcome. Because potency is uncertain when first starting the drug in opioid-exposed patients, there is a risk of inadvertent acute overdose if the starting dose is too high [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The half-life of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      is long (usually about 24 hours) but can vary widely between patients, ranging from 12 hours to more than 150 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/41\">",
"       41",
"      </a>",
"      ]. The half-life determines the time to approach steady state (five to six half-lives, irrespective of dose or route of administration). Clinicians have no way of knowing whether the patient who receives methadone will require a few days or a few weeks to reach steady state after stable dosing begins. Thus, there is a potential for accumulation of the drug for a prolonged period and patients may be at risk of late toxicity. Guidelines emphasize the need for caution when switching to methadone from other opioids [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies indicate that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      has the potential to prolong the QT interval [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/44,45\">",
"       44,45",
"      </a>",
"      ], a phenomenon that predisposes to a life-threatening cardiac arrhythmia, torsades du pointe. Although the risk of critical prolongation from methadone remains uncertain, caution should be used when prescribing high doses of methadone (eg, greater than 100 mg per day) or administering methadone to patients who have intrinsic heart disease or are receiving other drugs that prolong the QTc. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are as yet no established guidelines for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    in the medically ill. Unless otherwise determined by the goals of care, it is reasonable to check an electrocardiogram prior to methadone administration in the elderly and those otherwise predisposed to adverse cardiac effects, and to repeat this test if the dose must be increased repeatedly over time. The clinical response to prolongation of the QTc depends on many factors, including the severity of the abnormality, the availability of alternative measures for pain control, and the goals of care in the setting of advanced illness. Given that the focus is often on comfort in patients at the end of life, for those who are receiving benefit from methadone and who have chosen not to be resuscitated, careful QTc monitoring is probably not needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents not typically used in a palliative care setting include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       Meperidine",
"      </a>",
"      , propoxyphene, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      are available, but are not generally recommended because of an increased risk of side effects at higher doses. Meperidine and propoxyphene have active metabolites that can accumulate, particularly with renal insufficiency, and cause toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The commercially available partial opioid agonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      , and the mixed agonist-antagonists,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"       butorphanol",
"      </a>",
"      , dezocine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14038?source=see_link\">",
"       nalbuphine",
"      </a>",
"      , are not preferred because of a ceiling effect for analgesia and the capacity to induce withdrawal when administered to patients already receiving other opioids.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       Tramadol",
"      </a>",
"      , a centrally-acting analgesic with both opioid and monoaminergic effects, is widely used outside the United States. Tramadol also has a ceiling effect for analgesia and can lower the seizure threshold, characteristics that suggest first-line use of alternative pure mu agonists if they are available. A newer, mixed-mechanism drug,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/20/27975?source=see_link\">",
"       tapentadol",
"      </a>",
"      , also is available in the United States. Experience with this drug in populations with advanced illness is very limited.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Guidelines for opioid administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to effectively relieve pain using opioid drugs primarily depends upon the care involved in its administration, rather than the specific drug selected.",
"   </p>",
"   <p>",
"    For the patient who experiences unmanageable treatment-related toxicity during opioid dose adjustment (and therefore must be considered poorly responsive to the specific regimen), options include opioid rotation, the addition of a nonopioid analgesic or adjuvant analgesic, or the use of an intervention that may reduce the opioid requirement (including a trial of neuraxial drugs, a nerve block, or another nonpharmacologic therapy). At the end of life, pain that is refractory to treatment also may lead to a decision to offer palliative sedation.",
"   </p>",
"   <p>",
"    Guidelines for opioid therapy typically focus on selection of the route of administration, dosing, drug rotation, and treatment of expected side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Route",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral and transdermal routes generally are preferred for the long-term management of chronic pain (",
"    <a class=\"graphic graphic_table graphicRef80298 \" href=\"UTD.htm?26/36/27211\">",
"     table 2",
"    </a>",
"    ). For patients who can still swallow their own saliva, but can no longer take oral sustained-release medications, liquid oral concentrates of immediate release opioids can be given around the clock.",
"   </p>",
"   <p>",
"    However, the oral route may become unavailable as illness progresses. If transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    is available and a switch from the oral opioid to transdermal fentanyl is feasible, this strategy may be employed. If not, some other approach (typically continuous subcutaneous or intravenous delivery) must be used. With appropriate nursing support, the latter strategies can be carried out in the home environment. Other routes of administration are used less often. If doses are moderate and rectal administration is acceptable to the patient, suppositories can be used, either delivering a short-acting drug (commercially available",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    in the United States) or a modified-release tablet or capsule.",
"   </p>",
"   <p>",
"    The availability of \"rapid onset\" oral transmucosal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    formulations represents a potential advance for the treatment of breakthrough pain. Multiple alternative formulations are available and others are likely to become available for during the next few years. The role of these agents in the treatment of patients with advanced illness remains to be clarified. Clinical experience suggests that the relatively rapid onset of effect is a favorable outcome and particularly meaningful for a subpopulation of patients with breakthrough pain that increases quickly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H20#H20\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Management of breakthrough pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasional patients may benefit from neuraxial infusion and a local anesthetic (sometimes combined with other drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ), which can be delivered into the epidural space via a percutaneous or implanted catheter, or into the subarachnoid space via connection with an implanted pump. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with advanced illness and a life expectancy of several months or less, the most common approach is epidural infusion via a catheter that is tunneled and either penetrates the skin or is connected to a subcutaneous port. This technique can allow delivery of drug combinations, usually starting with an opioid and a local anesthetic. The doses employed are a fraction of those delivered systemically and, as a result, neuraxial analgesia can be particularly helpful when systemic drug therapy is associated with an unacceptable degree of somnolence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are opioid-naive and develop moderate to severe pain often are initially given access to a short-acting drug, usually a combination product containing hydrocodone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    , some other pure mu agonist, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    . Therapy usually is initiated on an \"as needed\" basis. Should pain persist or require frequent dosing, the drug is changed to a long-acting opioid formulation administered on a fixed schedule basis. A short-acting, \"as needed\" opioid may be added for breakthrough pain. If pain increases over time, the dose of the long-acting formulation can be increased by a reasonable percentage (usually 25 to 50 percent) or by an amount equal to the short-acting drug required during the prior days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H27#H27\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Dose titration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This general approach has become the standard of care in developed countries, but has not been shown to provide any benefit over the initial use of a long-acting drug, such as a modified-release oral opioid or transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    . As long as treatment with the latter drugs is begun with appropriate low doses, the management of chronic pain can start with a fixed scheduled regimen using a long-acting drug.",
"   </p>",
"   <p>",
"    There are few studies of rescue dosing, and the selection of a drug, dose and dosing interval is usually based on clinical experience. Except during therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    or transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , the rescue drug is usually the same drug as that administered on a fixed-schedule basis (eg, short-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    is offered as needed for breakthrough pain when modified-release oxycodone is the baseline opioid). There is no evidence, however, that results are better with this approach than when a different short-acting drug is used to supplement the baseline opioid. When methadone is used, a short-acting opioid, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , is typically coadministered.",
"   </p>",
"   <p>",
"    The size of the rescue dose is usually 5 to 15 percent of the total daily dose, and the dosing interval is every one hour when administered intravenously or every two hours when administered orally. The advent of the rapid-onset transmucosal formulations, which have been approved for the treatment of cancer-related breakthrough pain, provides another option in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H20#H20\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Management of breakthrough pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the route of administration, the key to successful opioid therapy is individualization of the dose through a process of repeated dose adjustment, combined with treatment of side effects. The dose should be gradually increased until either satisfactory pain relief occurs or the patient develops intolerable and unmanageable side effects. The absolute dose of opioid is immaterial as long as the balance between efficacy and adverse effects is favorable. Most patients attain a favorable balance between analgesia and side effects, and the dose usually is stable for a long period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H27#H27\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Dose titration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients experience treatment-limiting side effects as the dose of the opioid is increased. Those who initially appear to be poorly responsive to an opioid regimen may have a favorable outcome if the side effects are successfully managed so that the patient can tolerate the dose associated with adequate pain control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The assessment of opioid side effects in those with advanced illness can be challenging because of the existence of disease complications or comorbidities that may contribute to the problem, change the presentation, or alter the usual approach to therapy. The goals of care may be continually shifting in the context of far advanced illness and the need or appropriateness of interventions, such as a strategy to reduce somnolence, may change over time. Indeed, near the end of life, somnolence may be viewed as a positive effect of treatment.",
"   </p>",
"   <p>",
"    Notwithstanding the difficulties in assessing side effects, clinicians must be prepared to manage the common opioid side effects as a routine part of analgesic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/48\">",
"     48",
"    </a>",
"    ]. The most common problems related to pain management in populations with advanced illness are constipation and somnolence or cognitive impairment. Simple strategies for management are now widely used for these problems (",
"    <a class=\"graphic graphic_table graphicRef75786 \" href=\"UTD.htm?12/7/12412\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Opioid rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient who has unmanageable side effects without adequate pain relief during opioid titration may benefit from a switch to an alternative opioid drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H28#H28\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Using opioid rotation to manage poorly responsive pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When patients are switched from one opioid drug to another, the dose of the new drug is calculated from the equianalgesic dose table (",
"    <a class=\"graphic graphic_table graphicRef65027 \" href=\"UTD.htm?27/50/28461\">",
"     table 4",
"    </a>",
"    ). The dose of the new drug is then reduced to decrease the risk of toxicity caused by incomplete cross-tolerance.",
"   </p>",
"   <p>",
"    A common applied approach is to first reduce the calculated equianalgesic dose by 25 to 50 percent, with several exceptions. Factors to be considered in determining the actual dose include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In deciding on the specific dose within the adjusted range (eg, 25 to 50 percent reduction when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      is switched to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      ), clinical factors are key. If current side effects are severe or the patient is medically frail, the reduction should be relatively large and if the pain is severe the reduction should be relatively smaller [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the new drug is transdermal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      , the calculated dose is considered the equianalgesic dose (a safety factor has already been built into the conversion)",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      , the dose must be reduced by more, usually 75 percent to 90 percent, because of the prolonged half-life and high inter-patient variability. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Methadone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After this initial reduction in the calculated equianalgesic dose, a second dose adjustment of plus 15 percent should be considered depending on other factors that may suggest the need for added safety (eg, advanced age) or more analgesic effect (severe pain) (",
"    <a class=\"graphic graphic_table graphicRef59062 \" href=\"UTD.htm?30/36/31308\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     NONOPIOID DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonopioid analgesics include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (known as paracetamol outside the United States) and the nonsteroidal antiinflammatory drugs (NSAIDs) (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"     table 6",
"    </a>",
"    ). These drugs may be used for mild or moderate pain and can provide analgesia that is additive to that produced by the opioids. The addition of one of these agents to a patient who is experiencing an unfavorable balance between analgesia and side effects may improve the analgesia sufficiently to allow opioid dose reduction, and in this way convert a poorly responsive patient to one who is benefiting from the opioid regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=see_link\">",
"     \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      is the safest nonopioid drug and regular administration of this drug at three to four grams per day should be considered among the strategies that may enhance analgesia in populations with advanced illness.",
"     </li>",
"     <li>",
"      The NSAIDs all inhibit the enzyme cyclooxygenase (COX) in the periphery and central nervous system and are nonspecific analgesics. Based upon clinical observations, the NSAIDS are usually considered to be more efficacious in pain related to inflammatory lesions and bone pain, and less effective for neuropathic pain [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/51\">",
"       51",
"      </a>",
"      ]. They all have a ceiling dose for analgesia and are associated with the potential for toxicity that may limit their utility in patients with severe or advanced illness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"       \"NSAIDs: Therapeutic use and variability of response in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"       \"Nonselective NSAIDs: Overview of adverse effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NSAIDs are associated with several important toxicities that apply to all the members of this class:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSAIDs can produce gastrointestinal toxicity, the most serious manifestation of which is gastric or duodenal ulceration. The risk of ulcer is relatively higher in the elderly, those with prior history of NSAID-induced gastroduodenopathy, those with history of peptic ulcer, and those receiving a corticosteroid. The risk is reduced by coadministration of a gastroprotective agent (a proton pump inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      , or possibly a high dose H2 inhibitor) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/52-54\">",
"       52-54",
"      </a>",
"      ]. It is also lessened by the use of a NSAID that is a relatively specific inhibitor of the form of COX known as COX-2. The only COX-2 selective drug now available in the US is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      . This drug, or another of the NSAIDs with an established relatively low risk of GI toxicity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"       nabumetone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/43/42677?source=see_link\">",
"       choline magnesium trisalicylate",
"      </a>",
"      ), should be considered first in the setting of advanced illness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NSAIDs can cause renal toxicity (including acute renal failure). There is no evidence that any NSAID or NSAID subclass is relatively renal-sparing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NSAIDs can also induce fluid retention, which may be problematic for patients with heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parenteral NSAIDs may provide an opioid-sparing effect for patients undergoing procedures such as chest tube insertions or for postoperative pain relief. In the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    are available as injections, but only ketorolac has the potency of parenteral opioids and is useful in these patients. However, all parenteral NSAIDs should be used with caution in patients with preexisting renal insufficiency, hypoperfusion or those who are elderly. They should be avoided altogether in patients with asthma or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    sensitivity. Parenteral NSAIDs also carry a significant risk of gastrointestinal hemorrhage. When used, treatment should be limited to the lowest effective dose for the shortest period of time, not to exceed five days. However, the dose of ketorolac should be reduced in geriatric patients, 15 mg every six hours, with no more than 60 mg administered in a 24 hour period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adjuvant analgesic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adjuvant analgesic drug is most often considered toward the end of life in the settings of opioid-refractory neuropathic pain, bone pain, or pain related to bowel obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Neuropathic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathic pain may be directly related to an illness (eg, nerve compression from tumor) or to a comorbid condition (eg, chronic back pain with radiculopathy, diabetic peripheral neuropathic pain, or postherpetic neuralgia). In this setting, opioid therapy usually is tried first. If response is relatively poor, a trial of an adjuvant analgesic often is considered. There are numerous drugs in diverse classes (",
"    <a class=\"graphic graphic_table graphicRef56216 \" href=\"UTD.htm?1/58/1964\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The conventional strategy is to consider a corticosteroid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) or specific anticonvulsants and antidepressants as the first-line therapies. In the setting of advanced illness, when pain typically is associated with other symptoms, prescription of a corticosteroid (eg, dexamethasone 1 to 4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is very common. If another drug is needed to augment opioid analgesia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    usually is selected first, unless there is a comorbid depression, in which case one of the analgesic antidepressants (either a tricyclic drug such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    , or a serotonin-norepinephrine reuptake inhibitor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ) is used. Like the NSAIDs, these agents are available only in oral formulations and may not be useful when oral intake is diminished.",
"   </p>",
"   <p>",
"    For patients at the end of life, it can take a week or longer for the analgesic effect to be seen with these agents. In addition, anticonvulsants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    should not be discontinued abruptly because of the possibility of an acute pain flare or the development of seizures in those with a pre-existing seizure disorder; unless safety concerns require a more rapid withdrawal, tapering over at least one week is recommended. &nbsp;",
"   </p>",
"   <p>",
"    Parenteral therapies that may be useful for neuropathic pain in the setting of advanced illness include parenteral corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    by brief or continuous infusion, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    by infusion. The safe administration of these drugs requires an experienced clinician and nursing staff. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Bone pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone pain is the most common cause of pain in persons with cancer. The pharmacotherapy of these syndromes may benefit from a NSAID, a corticosteroid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], or an osteoclast inhibitor such as a bisphosphonate. Small controlled trials have yielded conflicting information about the potential for subcutaneous calcitonin to reduce metastatic bone pain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/57\">",
"     57",
"    </a>",
"    ]. Given the lack of consistent evidence, this treatment generally is not recommended, although an empirical trial could be considered when other treatments are unavailable or ineffective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of cancer pain syndromes\", section on 'Multifocal bone pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H30#H30\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Adjuvant drugs used for bone pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Bowel obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms associated with malignant bowel obstruction can usually be managed without a GI drainage procedure in the setting of advanced illness. In addition to an opioid, treatment usually involves administration of an anticholinergic drug (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    ) and the somatostatin analog,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Octreotide inhibits the secretion of gastric, pancreatic, and intestinal secretions, and reduces gastrointestinal motility [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H34#H34\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for the pain of bowel obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous nonpharmacologic therapies for pain and other symptoms. These include various psychological approaches (eg, guided imagery), treatments that have been conventionally labeled rehabilitative (eg, so-called modalities such as transcutaneous electrical nerve stimulation, therapeutic exercise, or splints), a large number of specific nerve blocks, and treatments that are usually considered alternative or complementary, which include acupuncture, massage, and other mind-body approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?12/37/12890/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32170?source=see_link\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to try any of these adjunctive approaches must consider the severity of disease, the patient's ability to work with the therapist, safety issues, availability, and cost. Some require specialist consultants and others could be considered within the purview of primary care providers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PALLIATIVE SEDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain can be adequately relieved in the vast majority of patients with conventional opioids. For the small percentage of patients with advanced illness at the end of life who have refractory pain, palliative sedation is an option. Palliative sedation is a therapeutic intervention defined as the intentional use of sedating medication (typically a short-acting benzodiazepine) to reduce consciousness with the goal of eliminating suffering. The indications and the process of palliative sedation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"./palliative-sedation?source=see_link\">",
"     \"Palliative sedation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       \"Patient information: Medical care during advanced illness (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       \"Patient information: Advance directives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain management is a key element in palliative care and the skills required to provide comfort and relieve other sources of suffering should be acquired by all clinicians involved in the care of populations with life-threatening illnesses. With appropriate use of available pharmacologic agents and other approaches, pain associated with advanced illness in the last weeks of life usually can be controlled.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/1\">",
"      von Gunten CF. Interventions to manage symptoms at the end of life. J Palliat Med 2005; 8 Suppl 1:S88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/2\">",
"      Buchanan RJ, Choi M, Wang S, Huang C. Analyses of nursing home residents in hospice care using the minimum data set. Palliat Med 2002; 16:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/3\">",
"      Emanuel EJ, Fairclough DL, Slutsman J, Emanuel LL. Understanding economic and other burdens of terminal illness: the experience of patients and their caregivers. Ann Intern Med 2000; 132:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/4\">",
"      van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain 2007; 132:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/5\">",
"      Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 2011; 29:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/6\">",
"      Kimball LR, McCormick WC. The pharmacologic management of pain and discomfort in persons with AIDS near the end of life: use of opioid analgesia in the hospice setting. J Pain Symptom Manage 1996; 11:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/7\">",
"      Nordgren L, S&ouml;rensen S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur J Cardiovasc Nurs 2003; 2:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/8\">",
"      Ehde DM, Gibbons LE, Chwastiak L, et al. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler 2003; 9:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/9\">",
"      Kong KH, Woon VC, Yang SY. Prevalence of chronic pain and its impact on health-related quality of life in stroke survivors. Arch Phys Med Rehabil 2004; 85:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/10\">",
"      Shega JW, Hougham GW, Stocking CB, et al. Patients dying with dementia: experience at the end of life and impact of hospice care. J Pain Symptom Manage 2008; 35:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/11\">",
"      Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994; 30A:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/12\">",
"      Vogl D, Rosenfeld B, Breitbart W, et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage 1999; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/13\">",
"      Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990; 5:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/14\">",
"      Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/15\">",
"      A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995; 274:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/16\">",
"      Goldberg GR, Morrison RS. Pain management in hospitalized cancer patients: a systematic review. J Clin Oncol 2007; 25:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/17\">",
"      Higginson IJ, Gao W. Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study. J Clin Oncol 2012; 30:4373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/18\">",
"      Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA 1998; 279:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/19\">",
"      Pargeon KL, Hailey BJ. Barriers to effective cancer pain management: a review of the literature. J Pain Symptom Manage 1999; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/20\">",
"      Fineberg IC, Wenger NS, Brown-Saltzman K. Unrestricted opiate administration for pain and suffering at the end of life: knowledge and attitudes as barriers to care. J Palliat Med 2006; 9:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/21\">",
"      Paice JA, Toy C, Shott S. Barriers to cancer pain relief: fear of tolerance and addiction. J Pain Symptom Manage 1998; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/22\">",
"      Gunnarsdottir S, Donovan HS, Serlin RC, et al. Patient-related barriers to pain management: the Barriers Questionnaire II (BQ-II). Pain 2002; 99:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/23\">",
"      Ward SE, Goldberg N, Miller-McCauley V, et al. Patient-related barriers to management of cancer pain. Pain 1993; 52:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/24\">",
"      Billings JA. What is palliative care? J Palliat Med 1998; 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/25\">",
"      Saunders C. A personal therapeutic journey. BMJ 1996; 313:1599.",
"     </a>",
"    </li>",
"    <li>",
"     Consensus Project for Best Practices in Palliative Care file://www.nationalconsensusproject.org/Guideline.pdf (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/27\">",
"      Gruneir A, Mor V, Weitzen S, et al. Where people die: a multilevel approach to understanding influences on site of death in America. Med Care Res Rev 2007; 64:351.",
"     </a>",
"    </li>",
"    <li>",
"     NHPCO Facts and Figures: Hospice Care in America 2011 Edition file://www.nhpco.org (Accessed on April 12, 2011). (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/29\">",
"      Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc 2003; 4:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/30\">",
"      A&iuml;ssaoui Y, Zeggwagh AA, Zekraoui A, et al. Validation of a behavioral pain scale in critically ill, sedated, and mechanically ventilated patients. Anesth Analg 2005; 101:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/31\">",
"      G&eacute;linas C, Johnston C. Pain assessment in the critically ill ventilated adult: validation of the Critical-Care Pain Observation Tool and physiologic indicators. Clin J Pain 2007; 23:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/32\">",
"      Desbiens NA, Mueller-Rizner N. How well do surrogates assess the pain of seriously ill patients? Crit Care Med 2000; 28:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/33\">",
"      Grond S, Zech D, Schug SA, et al. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991; 6:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/34\">",
"      D'Honneur G, Gilton A, Sandouk P, et al. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology 1994; 81:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/35\">",
"      Faura CC, Moore RA, Horga JF, et al. Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manage 1996; 11:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/36\">",
"      Tiseo PJ, Thaler HT, Lapin J, et al. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61:47.",
"     </a>",
"    </li>",
"    <li>",
"     Sj&ouml;gren P. Clinical implications of morphine metabolites. In: in Palliative Care, Portenoy RK, Bruera EB (Eds), Oxford University Press, New York 1997. Vol 1, p.163.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/38\">",
"      Bruera E, Neumann CM. Role of methadone in the management of pain in cancer patients. Oncology (Williston Park) 1999; 13:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/39\">",
"      Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995; 187:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/40\">",
"      Scholes CF, Gonty N, Trotman IF. Methadone titration in opioid-resistant cancer pain. Eur J Cancer Care (Engl) 1999; 8:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/41\">",
"      Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988; 33:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/42\">",
"      Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002; 5:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/43\">",
"      Manfredi PL, Houde RW. Prescribing methadone, a unique analgesic. J Support Oncol 2003; 1:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/44\">",
"      Cruciani RA, Sekine R, Homel P, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005; 29:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/45\">",
"      Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387.",
"     </a>",
"    </li>",
"    <li>",
"     Max MB, Payne R, Edwards WT, et al. American Pain Society Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 4th, American Pain Society, Glenview, IL 2005.",
"    </li>",
"    <li>",
"     Fine P, Portenoy RK. Opioid analgesia, 2nd, McGraw-Hill, New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/48\">",
"      Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006; 74:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/49\">",
"      Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002; 20:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/50\">",
"      Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996; 78:852.",
"     </a>",
"    </li>",
"    <li>",
"     Wallenstein DJ, Portenoy RK. Nonopioid and adjuvant analgesics. In: Principles and Practice of Palliative Care and Supportive Oncology, Berger AM, Portenoy RK (Eds), Lippincott-Raven, Philadelphia 2002. p.84.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/52\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/53\">",
"      Yeomans ND, Tulassay Z, Juh&aacute;sz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/54\">",
"      Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996; 156:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/55\">",
"      Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/56\">",
"      Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/57\">",
"      Martinez-Zapata MJ, Roque i Figuls M, Alonso-Coello P. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/58\">",
"      Ripamonti C, Twycross R, Baines M, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001; 9:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/59\">",
"      Fainsinger RL, Spachynski K, Hanson J, Bruera E. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage 1994; 9:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/60\">",
"      Mystakidou K, Tsilika E, Kalaidopoulou O, et al. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial. Anticancer Res 2002; 22:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/37/12890/abstract/61\">",
"      Pan CX, Morrison RS, Ness J, et al. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage 2000; 20:374.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2209 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12890=[""].join("\n");
var outline_f12_37_12890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE OF PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Undertreatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PAIN MANAGEMENT AS A COMPONENT OF PALLIATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Goal setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Care setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PAIN ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OPIOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Morphine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other short half-life opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fentanyl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Levorphanol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Methadone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Guidelines for opioid administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Route",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Opioid rotation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      NONOPIOID DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adjuvant analgesic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Bone pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      NONPHARMACOLOGIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PALLIATIVE SEDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2209\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2209|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/45/35537\" title=\"figure 1\">",
"      Symptoms in the last six months of life in cancer patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2209|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/31/11760\" title=\"table 1\">",
"      Select opioids chronic pain and equianalgesic doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/36/27211\" title=\"table 2\">",
"      Analgesic routes admin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/7/12412\" title=\"table 3\">",
"      Pharma Rx opioid sd eff",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/50/28461\" title=\"table 4\">",
"      Opioid analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/36/31308\" title=\"table 5\">",
"      Guidelines opioid rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24431\" title=\"table 6\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/58/1964\" title=\"table 7\">",
"      Adjuvant analgesics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19477?source=related_link\">",
"      Ethical considerations in effective pain management at the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./palliative-sedation?source=related_link\">",
"      Palliative sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_37_12891="Indications for NMB";
var content_f12_37_12891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for the use of neuromuscular blocking agents in the ICU",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        To facilitate short procedures under general anesthesia (endotracheal",
"intubation, bronchoscopy, gastrointestinal endoscopy, specialized",
"radiologic procedures)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To facilitate mechanical ventilation (increase chest wall compliance,",
"prevent poorly coordinated respiratory movements, reduce peak airway",
"pressures, and",
"facilitate permissive hypercapnia) despite adequate sedation and",
"analgesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To reduce muscle oxygen consumption*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To prevent respiratory or other movements, and coughing on tracheal",
"suction in patients with increased intracranial pressure or massive",
"hemoptysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To facilitate treatment of medical conditions associated with increased",
"muscle activity, including tetanus, neuroleptic malignant syndrome, or",
"status epilepticus&bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Sedative drugs alone are usually sufficient.",
"     <br>",
"      &bull; NMBAs gain immediate control but do nothing to terminate central epileptic activity.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12891=[""].join("\n");
var outline_f12_37_12891=null;
var title_f12_37_12892="Parenteral rx enterococci";
var content_f12_37_12892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parenteral therapy for susceptible enterococci",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Regimen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dosage and route",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Preferred options for monotherapy*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ampicillin&bull;",
"      </td>",
"      <td>",
"       6-12 g per 24 hours in 4 to 6 equally divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Penicillin G",
"      </td>",
"      <td>",
"       18-30 million units per 24 hours either continuously or in 6 equally divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vancomycin",
"      </td>",
"      <td>",
"       30 mg/kg per 24 hours in 2 equally divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       <p>",
"        Options for combination therapy&Delta;:",
"       </p>",
"       <p>",
"        One of above agents, PLUS one of the following agents (for bactericidal activity)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gentamicin&loz;",
"      </td>",
"      <td>",
"       3 mg/kg per 24 hours in 3 equally divided doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Streptomycin&sect;",
"      </td>",
"      <td>",
"       15 mg/kg per 24 hours in 2 equally divided doses",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Daptomycin and tigecycline are also approved for use in complicated skin and skin structure infections due to vancomycin-susceptible E faecalis; in addition, tigecycline has approval for complicated intraabdominal infections associated with E. faecalis.",
"     <br>",
"      &bull; Infections due to beta lactamase producing enterococci requiring parenteral therapy may be treated with ampicillin-sulbactam (12 g per 24 hours) or vancomycin.",
"      <br>",
"       &Delta; Synergistic activity of a cell wall-active agent in combination with gentamicin or streptomycin is required for bactericidial activity, which is warranted in the setting of invasive infections such as endocarditis, meningitis, and bacteremia in the setting of valvulopathy and/or critical illness. When combination therapy with an aminoglycoside is precluded by high-level resistance to both gentamicin and streptomycin, ceftriaxone in combination with ampicillin could be considered. (See \"Antimicrobial therapy of native valve endocarditis\" section on Enterococcus).",
"       <br>",
"        &loz; In patients with normal renal function, gentamicin dosing should be adjusted to achieve a 1-hour serum concentration of 3 mcg/mL and a trough concentration of &lt;1 mcg/mL.",
"        <br>",
"         &sect; In patients with normal renal function, streptomycin dosing should be adjusted to achieve a 1-hour serum concentration of 20 to 35 mcg/mL and a trough concentration of &lt;10 mcg/mL.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12892=[""].join("\n");
var outline_f12_37_12892=null;
var title_f12_37_12893="Empiric abx purulent mening";
var content_f12_37_12893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for empiric antimicrobial therapy for purulent meningitis based on patient age and specific predisposing condition*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Predisposing factor",
"      </td>",
"      <td class=\"subtitle1\">",
"       Common bacterial pathogens",
"      </td>",
"      <td class=\"subtitle1\">",
"       Antimicrobial therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"3\">",
"       Age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &lt;1 month",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        Streptococcus agalactiae",
"       </em>",
"       ,",
"       <em>",
"        Escherichia coli",
"       </em>",
"       ,",
"       <em>",
"        Listeria monocytogenes",
"       </em>",
"       ,",
"       <em>",
"        Klebsiella",
"       </em>",
"       species",
"      </td>",
"      <td class=\"sublist_other\">",
"       Ampicillin plus cefotaxime; OR ampicillin plus an aminoglycoside",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1-23 months",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        Streptococcus pneumoniae",
"       </em>",
"       ,",
"       <em>",
"        Neisseria meningitidis",
"       </em>",
"       ,",
"       <em>",
"        S. agalactiae",
"       </em>",
"       ,",
"       <em>",
"        Haemophilus influenzae",
"       </em>",
"       ,",
"       <em>",
"        E. coli",
"       </em>",
"      </td>",
"      <td class=\"sublist_other\">",
"       Vancomycin plus a third-generation cephalosporin&bull;&Delta;&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2-50 years",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        N. meningitidis",
"       </em>",
"       ,",
"       <em>",
"        S. pneumoniae",
"       </em>",
"      </td>",
"      <td class=\"sublist_other\">",
"       Vancomycin plus a third-generation cephalosporin&bull;&Delta;&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &gt;50 years",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        S. pneumoniae",
"       </em>",
"       ,",
"       <em>",
"        N. meningitidis",
"       </em>",
"       ,",
"       <em>",
"        L. monocytogenes",
"       </em>",
"       , aerobic gram-negative bacilli",
"      </td>",
"      <td class=\"sublist_other\">",
"       Vancomycin plus ampicillin plus a third-generation cephalosporin&bull;&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"3\">",
"       Head trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Basilar skull fracture",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        S. pneumoniae",
"       </em>",
"       ,",
"       <em>",
"        H. influenzae",
"       </em>",
"       , group A beta-hemolytic streptococci",
"      </td>",
"      <td class=\"sublist_other\">",
"       Vancomycin plus a third-generation cephalosporin&bull;&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Penetrating trauma",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        Staphylococcus aureus",
"       </em>",
"       , coagulase-negative staphylococci (especially",
"       <em>",
"        Staphylococcus epidermidis",
"       </em>",
"       ), aerobic gram-negative bacilli (including",
"       <em>",
"        Pseudomonas aeruginosa",
"       </em>",
"       )",
"      </td>",
"      <td class=\"sublist_other\">",
"       Vancomycin plus cefepime; OR vancomycin plus ceftazidime; OR vancomycin plus meropenem",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postneurosurgery",
"      </td>",
"      <td>",
"       Aerobic gram-negative bacilli (including",
"       <em>",
"        P. aeruginosa",
"       </em>",
"       ),",
"       <em>",
"        S. aureus",
"       </em>",
"       , coagulase-negative staphylococci (especially",
"       <em>",
"        S. epidermidis",
"       </em>",
"       )",
"      </td>",
"      <td>",
"       Vancomycin plus cefepime; OR vancomycin plus ceftazidime; OR vancomycin plus meropenem",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immunocompromised state",
"      </td>",
"      <td>",
"       <em>",
"        S. pneumoniae",
"       </em>",
"       ,",
"       <em>",
"        N. meningitidis",
"       </em>",
"       ,",
"       <em>",
"        L. monocytogenes",
"       </em>",
"       , aerobic gram-negative bacilli (including",
"       <em>",
"        P. aeruginosa",
"       </em>",
"       )",
"      </td>",
"      <td>",
"       Vancomycin plus ampicillin plus cefepime; OR vancomycin plus ampicillin plus meropenem",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For recommended dosages for adults, see the table \"Recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis\".",
"     <br>",
"      &bull; Ceftriaxone or cefotaxime.",
"      <br>",
"       &Delta; Some experts would add rifampin if dexamethasone is also given.",
"       <br>",
"        &loz; Add ampicillin if meningitis caused by Listeria monocytogenes is suspected.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel, AR, Hartman, BJ, Kaplan, SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy;2004 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12893=[""].join("\n");
var outline_f12_37_12893=null;
var title_f12_37_12894="Causes of liver allograft dysfunction";
var content_f12_37_12894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Causes of liver allograft dysfunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 265px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12894=[""].join("\n");
var outline_f12_37_12894=null;
var title_f12_37_12895="Pendulum stretch exercise PI";
var content_f12_37_12895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pendulum stretch exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To do this exercise, you can sit or stand. Relax your arm and let it hang down. Move your arm back and forth, then side to side, and then around in small circles in both directions. After about a week, you can make the exercise harder by making bigger movements or holding a weight in your hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_37_12895=[""].join("\n");
var outline_f12_37_12895=null;
